<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS199535</article-id><article-id pub-id-type="doi">10.1101/2024.10.16.618635</article-id><article-id pub-id-type="archive">PPR927270</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Pre-existing intratumoral stem-like CD8<sup>+</sup> T-cells drive radiotherapy-induced tumor control</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Köksal</surname><given-names>Hakan</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Herbst</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Perreira</surname><given-names>Paulo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nater</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Regli</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Boudjeniba</surname><given-names>Cheïma</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Borgoni</surname><given-names>Nese Erdem</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cecconi</surname><given-names>Virginia</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>van den Broek</surname><given-names>Maries</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Institute of Experimental Immunology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02crff812</institution-id><institution>University of Zurich</institution></institution-wrap>, <country country="CH">Switzerland</country></aff><aff id="A2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0495fxg12</institution-id><institution>Institut Pasteur</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f82e368</institution-id><institution>Université Paris Cité</institution></institution-wrap>, <postal-code>F-75015</postal-code><city>Paris</city>, <country country="FR">France</country></aff><author-notes><corresp id="CR1">
<label>*</label>Corresponding author. Winterthurerstrasse 190, 8057 Zurich, Switzerland. <email>vandenbroek@immunology.uzh.ch</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>20</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>18</day><month>10</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><title>Summary</title><p id="P1">CD8<sup>+</sup> T-cells are essential for spontaneous and therapy-induced restriction of tumor progression. Upon radiotherapy, these pre-existing CD8<sup>+</sup> T-cells expand rapidly after their initial decline and are essential and sufficient for early tumor control. Stem-like CD8<sup>+</sup> T-cells proliferate and differentiate into effector CD8<sup>+</sup> T-cells in response to radiotherapy and are thus key determinants of therapy efficacy. Our findings highlight the critical role of intratumoral stem-like CD8<sup>+</sup> T-cells in driving radiotherapy-induced anti-tumor immunity. Our study provides deeper insights into the dynamic behavior of CD8<sup>+</sup> T-cells and their critical involvement in tumor control following radiotherapy.</p></abstract><kwd-group><kwd>Radiotherapy</kwd><kwd>stem-like CD8<sup>+</sup> T-cells</kwd><kwd>TCF-1</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Tumors must evade immune control, specifically T-cells, to progress <sup><xref ref-type="bibr" rid="R1">1</xref></sup>. For instance, the density of CD8<sup>+</sup> T-cells in tumors correlates with better survival in most tumor types <sup><xref ref-type="bibr" rid="R2">2</xref></sup>, and mobilizing CD8<sup>+</sup> T-cell-mediated immunity by immune checkpoint inhibitors has revolutionized the treatment of cancer <sup><xref ref-type="bibr" rid="R3">3</xref></sup>.</p><p id="P3">Radiotherapy is a frequently used treatment for cancer; approximately half of all cancer patients will receive radiotherapy at some point <sup><xref ref-type="bibr" rid="R4">4</xref></sup>. In addition to its genotoxic effect on cancer cells, radiotherapy promotes a local inflammatory response that supports tumor-specific immunity. For example, irradiated tumors have a higher density of tumor-associated effector CD8<sup>+</sup> T-cells than non-irradiated tumors, and in fact, the efficacy of radiotherapy in pre-clinical models depends on CD8<sup>+</sup> T-cells <sup><xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref></sup>. Several studies have addressed how radiotherapy supports tumor-specific immunity, and various factors were suggested, including type I interferon (IFN) <sup><xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R9">9</xref></sup>, increased expression of major histocompatibility complex (MHC) class I molecules and tumor-associated antigens <sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11">11</xref></sup>, and maturation of tumor-associated dendritic cells (DCs) <sup><xref ref-type="bibr" rid="R5">5</xref>–<xref ref-type="bibr" rid="R7">7</xref></sup>. Despite these observations, how radiotherapy influences the dynamics of different CD8<sup>+</sup> T-cell subsets in the tumor remains unclear.</p><p id="P4">Tumor-infiltrating CD8<sup>+</sup> T-cells display considerable inter- and intratumor heterogeneity in clinical and preclinical samples <sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref></sup>. Besides effector and memory cells, tumors contain CD8<sup>+</sup> T-cells at different stages of differentiation including exhausted and dysfunctional exhausted subsets <sup><xref ref-type="bibr" rid="R13">13</xref></sup>. Chronic exposure to antigens triggers an epigenetic differentiation program in T-cells that severely impairs their effector functions, metabolic fitness, and induces the expression of inhibitory receptors like PD-1 <sup><xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref></sup>. This exhausted state is generally considered terminal. However, the proliferation of intratumoral CD8<sup>+</sup> T-cells after PD-1 blockade <sup><xref ref-type="bibr" rid="R16">16</xref></sup> suggests that not all exhausted cells are terminal. In fact, a subset of virus-specific CD8<sup>+</sup> T-cells co-expressing the inhibitory receptor PD-1 and the transcription factor T-cell factor 1 (TCF-1, encoded by <italic>Tcf7</italic>) has been shown to maintain immune responses during chronic infections <sup><xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R19">19</xref></sup>. These so-called stem-like CD8<sup>+</sup> T-cells (TCF-1<sup>+</sup> PD-1<sup>+</sup> TIM-3<sup>-</sup>, also known as progenitor exhausted or T<sub>PEX</sub>) are capable of asymmetric cell division, which allows them to both self-renew and generate effector CD8<sup>+</sup> T cells (TCF-1<sup>-</sup> PD-1<sup>+</sup> TIM-3<sup>+</sup>) at the same time <sup><xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R21">21</xref></sup>. The frequency of intratumoral stem-like CD8<sup>+</sup> T-cells correlates with clinical response to PD-1 blockade <sup><xref ref-type="bibr" rid="R22">22</xref>–<xref ref-type="bibr" rid="R24">24</xref></sup>, which has stimulated wide interest in this subset. Additionally, tumor-draining lymph nodes have been identified as reservoirs of stem-like CD8<sup>+</sup> T-cells that migrate into the tumor and play a crucial role in sustaining the anti-tumor immune response <sup><xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R26">26</xref></sup>. However, it remains unclear how radiotherapy influences these intratumoral stem-like CD8<sup>+</sup> T cells and whether they play a role in the therapeutic efficacy of radiotherapy.</p><p id="P5">In this study, we explore how intratumoral CD8<sup>+</sup> T-cells respond to radiotherapy. We propose that radiotherapy drives the differentiation and proliferation of intratumoral stem-like CD8<sup>+</sup> T-cells, thereby playing an important role in tumor control.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>Radiotherapy leads to activation and differentiation of intratumoral CD8<sup>+</sup> T-cells</title><p id="P6">To investigate how radiotherapy affects the dynamics of CD8<sup>+</sup> T-cells within the tumor microenvironment, we irradiated C57BL/6 mice bearing a subcutaneous MC38 tumor with a single dose of 20 Gy (<xref ref-type="supplementary-material" rid="SD1">Figure S1A</xref>). Radiotherapy resulted in significant tumor control, both in size (<xref ref-type="supplementary-material" rid="SD1">Figure S1B</xref>) and weight (<xref ref-type="supplementary-material" rid="SD1">Figure S1C</xref>). Nine days after radiotherapy, we analyzed intratumoral CD8<sup>+</sup> T-cells by multi-parameter spectral flow cytometry to assess radiotherapy-induced phenotypic and functional changes (<xref ref-type="supplementary-material" rid="SD1">Figure S1D</xref>). Consistent with previous findings <sup><xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R28">28</xref></sup>, the number of intratumoral CD8<sup>+</sup> T-cells was significantly higher after radiotherapy (<xref ref-type="supplementary-material" rid="SD1">Figure S1E</xref>). Furthermore, after gating on CD8<sup>+</sup> T-cells, we observed a decreased frequency of CD62L<sup>+</sup>, an increased frequency of PD-1<sup>+</sup> and of TIM-3<sup>+</sup> cells (<xref ref-type="supplementary-material" rid="SD1">Figure S1F</xref>), and a higher frequency of granzyme B-positive (GZMB<sup>+</sup>) cells (<xref ref-type="supplementary-material" rid="SD1">Figure S1G</xref>). We observed an increased frequency of Ki-67<sup>+</sup>intratumoral CD8<sup>+</sup> T-cells (<xref ref-type="supplementary-material" rid="SD1">Figure S1H</xref>). Uniform Manifold Approximation and Projection (UMAP) visualization, combined with Rphenograph clustering, showed a distinct clustering of intratumoral CD8<sup>+</sup> T-cells after radiotherapy (<xref ref-type="supplementary-material" rid="SD1">Figure S1I</xref>). The accompanying heatmap illustrates the relative expression of key markers across different clusters, enabling the simultaneous analysis of multiple markers and providing a comprehensive view of T-cell states (<xref ref-type="supplementary-material" rid="SD1">Figure S1J</xref>). In summary, these results suggest that radiotherapy induces the differentiation and proliferation of intratumoral CD8<sup>+</sup> T-cells (<xref ref-type="supplementary-material" rid="SD1">Figure S1K</xref>).</p></sec><sec id="S4"><title>Pre-existing intratumoral CD8<sup>+</sup> T-cells are sufficient for the therapeutic efficacy of radiotherapy</title><p id="P7">To study tumor-specific CD8<sup>+</sup> T-cells, we used ovalbumin-expressing MC38 cells (MC38-OVA) as tumor model (<xref ref-type="supplementary-material" rid="SD1">Figure S2A</xref>). We demonstrated that the therapeutic efficacy of radiotherapy depends on CD8<sup>+</sup> T-cells (<xref ref-type="supplementary-material" rid="SD1">Figures S2A-D</xref>), which is in agreement with previously published work <sup><xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R30">30</xref></sup>. While the involvement of CD8<sup>+</sup> T-cells in radiotherapy-dependent tumor control has been established by multiple studies, it is less clear whether <italic>de novo</italic> recruited or pre-existing intratumoral CD8<sup>+</sup> T-cells are most important. To address this question, we injected mice with FTY720 (fingolimod) immediately before radiotherapy. FTY720 prevents the egress of lymphocytes from secondary lymphoid organs into the blood <sup><xref ref-type="bibr" rid="R31">31</xref></sup>, thereby blocking <italic>de novo</italic> infiltration into the tumor tissue (<xref ref-type="fig" rid="F1">Figures 1A</xref> and <xref ref-type="supplementary-material" rid="SD1">S3A</xref>). We will use the term “pre-existing intratumoral” for CD8<sup>+</sup> T-cells that were present in the tumor before blocking new infiltration by FTY720, and the term “intratumoral” for all CD8<sup>+</sup> T-cells in the tumor including pre-existing and newly infiltrated cells <sup><xref ref-type="bibr" rid="R32">32</xref></sup>. We found that FTY720 did not influence the efficacy of radiotherapy (<xref ref-type="fig" rid="F1">Figures 1B and 1C</xref>) or its effect on total and tumor-specific intratumoral CD8<sup>+</sup> T-cells (<xref ref-type="fig" rid="F1">Figures 1D and 1G</xref>). Despite FTY720 preventing <italic>de novo</italic> infiltration, the absolute number of intratumoral CD8<sup>+</sup> T-cells was higher in irradiated tumors, suggesting that radiotherapy induces differentiation and proliferation of pre-existing intratumoral CD8<sup>+</sup> T-cells. The UMAP visualization of clusters showed radiotherapy-induced differences in CD8<sup>+</sup> T-cell clustering, which were not affected by FTY720 treatment. (<xref ref-type="supplementary-material" rid="SD1">Figure S3B</xref>). The heatmap illustrates the relative expression levels of markers across different clusters (<xref ref-type="supplementary-material" rid="SD1">Figure S3C</xref>). These clusters confirm that radiotherapy promotes differentiation and increases the frequency of SIINFEKL-specific CD8<sup>+</sup> T-cells (<xref ref-type="supplementary-material" rid="SD1">Figure S3C</xref>), and these changes were unaffected by FTY720 (<xref ref-type="supplementary-material" rid="SD1">Figure S3D</xref>). The observation that the frequency of cluster 11 (Ki67<sup>high</sup>), significantly decreased after radiotherapy, regardless of FTY720 (<xref ref-type="supplementary-material" rid="SD1">Figure S3D</xref>), suggests that the initial radiotherapy-induced proliferative response diminishes nine days after radiotherapy. We repeated the experiment using the B16-OVA melanoma cell line (<xref ref-type="supplementary-material" rid="SD1">Figure S4A</xref>) and obtained comparable results (<xref ref-type="supplementary-material" rid="SD1">Figures S4B-F</xref>), indicating that our findings are not restricted to a single experimental model.</p></sec><sec id="S5"><title>Radiotherapy induces proliferation and differentiation of pre-existing intratumoral CD8<sup>+</sup> T-cells</title><p id="P8">To understand the dynamics of pre-existing intratumoral CD8<sup>+</sup> T-cells, we performed multiparameter single-cell mapping at different time points following radiotherapy. One (d1) or three days (d3) after radiotherapy (<xref ref-type="fig" rid="F2">Figure 2A</xref>), no therapeutic effect was yet detectable (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Compared to untreated tumors, the number of pre-existing intratumoral CD8<sup>+</sup> T-cells was significantly lower on day 1 but increased by day 3 (<xref ref-type="fig" rid="F2">Figure 2C</xref>). Phenotypic and functional analysis revealed minimal changes, except for a significant decrease in Ki-67<sup>+</sup> CD8<sup>+</sup> T-cells on day 1, suggesting an increased sensitivity of proliferating CD8<sup>+</sup> T-cells to radiotherapy-induced cell death (<xref ref-type="supplementary-material" rid="SD1">Figures S5A and S5B</xref>). UMAP and clustering analysis supported these findings, showing no significant clustering differences apart from a reduced frequency of the Ki-67<sup>high</sup> cluster (<xref ref-type="supplementary-material" rid="SD1">Figures S5C-E</xref>).</p><p id="P9">On days six (d6) and nine (d9) after radiotherapy, we observed progressive tumor reduction in both size and weight, indicating ongoing tumor control (<xref ref-type="fig" rid="F2">Figures 2D-F</xref>). Correspondingly, the number of pre-existing intratumoral CD8<sup>+</sup> T-cells continued to increase, suggesting that CD8<sup>+</sup> T-cell proliferation remains active during this period (<xref ref-type="fig" rid="F2">Figure 2G</xref>). Although no significant changes were observed in the frequency of early differentiated CD62L<sup>+</sup> CD8<sup>+</sup> T-cells, we observed an increase in differentiated CD8<sup>+</sup> T-cells expressing PD-1 and TIM-3 at both time points (<xref ref-type="fig" rid="F2">Figure 2H</xref>). Additionally, the frequency of GZMB<sup>+</sup> and SIINFEKL-specific CD8<sup>+</sup> T-cells continued to increase between day 6 and 9 (<xref ref-type="fig" rid="F2">Figure 2I</xref>). Consistent with earlier observations (<xref ref-type="fig" rid="F1">Figure 1F</xref>), the frequency of Ki-67<sup>+</sup> CD8<sup>+</sup> T-cells significantly increased on day 6, followed by a decrease on day 9, indicating that radiotherapy induces a transient proliferative response in pre-existing intratumoral CD8<sup>+</sup> T-cells. UMAP analysis further reflected these dynamic changes (<xref ref-type="supplementary-material" rid="SD1">Figures S6A-C</xref>). The frequency of clusters with high Ki-67 expression, such as cluster 4, peaked on day 6 and declined by day 9, corroborating our findings (<xref ref-type="supplementary-material" rid="SD1">Figure S6C</xref>).</p></sec><sec id="S6"><title>Radiotherapy induces proliferation and differentiation of pre-existing intratumoral stem-like CD8<sup>+</sup> T-cells</title><p id="P10">To gain a deeper understanding of the radiotherapy-induced changes in intratumoral CD8<sup>+</sup> T-cells, we performed single-cell RNA sequencing on sorted pre-existing and intratumoral CD8<sup>+</sup> T-cells six days after radiotherapy (<xref ref-type="fig" rid="F3">Figure 3A</xref>). We used the ProjecTILs package <sup><xref ref-type="bibr" rid="R33">33</xref></sup> to annotate the intratumoral CD8<sup>+</sup> T-cells and identified five distinct CD8<sup>+</sup> T-cell phenotypes: naïve-like, early active, stem-like, effector/memory, and exhausted (<xref ref-type="fig" rid="F3">Figure 3B</xref>). These differentiation states were correctly annotated, as confirmed by radar plots (<xref ref-type="supplementary-material" rid="SD1">Figure S7A</xref>) and violin plots (<xref ref-type="supplementary-material" rid="SD1">Figure S7B</xref>). Radiotherapy reduced the frequency of naïve-like intratumoral CD8<sup>+</sup> T-cells, regardless of FTY720 treatment (<xref ref-type="fig" rid="F3">Figures 3C</xref> and <xref ref-type="supplementary-material" rid="SD1">S8</xref>). Without FTY720, there was an increase in early activated and effector/memory CD8<sup>+</sup> T-cell states, while blocking new infiltration led to more exhausted CD8<sup>+</sup> T-cells. This suggests that pre-existing CD8<sup>+</sup> T-cells are more differentiated and exhausted compared to intratumoral CD8<sup>+</sup> T-cells, which likely include newly infiltrated cells in earlier differentiation states (<xref ref-type="fig" rid="F3">Figures 3C</xref> and <xref ref-type="supplementary-material" rid="SD1">S8</xref>).</p><p id="P11">Further analysis of exhausted CD8<sup>+</sup> T-cells revealed five distinct clusters (<xref ref-type="supplementary-material" rid="SD1">Figure S9A</xref>). We used single-cell gene signature scoring using the UCell package to characterize these clusters <sup><xref ref-type="bibr" rid="R34">34</xref></sup>. Among the two most abundant clusters, cluster 0 exhibited pronounced signatures of exhaustion and interferon response, while cluster 1 showed a strong proliferation signature (<xref ref-type="supplementary-material" rid="SD1">Figures S9B and S9C</xref>). After radiotherapy, cluster 0 was significantly enriched in total intratumoral CD8<sup>+</sup> T-cells, supporting our observation that radiotherapy promotes differentiation of pre-existing intratumoral CD8<sup>+</sup> T-cells. Further, pre-existing intratumoral CD8<sup>+</sup> T-cells were significantly enriched in cluster 1, indicating a robust radiotherapy-induced proliferative response (<xref ref-type="supplementary-material" rid="SD1">Figure S9D</xref>). To further validate these findings, we applied a threshold to the G1S and G2M UCell scores for all exhausted CD8<sup>+</sup> T-cells, classifying cells with scores above this threshold as proliferating. We found that the frequency of proliferating exhausted CD8<sup>+</sup> T-cells was indeed higher in pre-existing intratumoral CD8<sup>+</sup> T-cells after radiotherapy (<xref ref-type="supplementary-material" rid="SD1">Figure S9E</xref>). Additionally, there was a significant increase in <italic>Mki67</italic> expression after radiotherapy, especially in pre-existing CD8<sup>+</sup> T-cells (<xref ref-type="supplementary-material" rid="SD1">Figure S9F</xref>).</p><p id="P12">ProjecTILs package effectively identified stem-like CD8<sup>+</sup> T-cells, a subset that has been challenging to detect using flow cytometry in our tumor models (<xref ref-type="fig" rid="F3">Figures 3B and 3C</xref>). Stem-like CD8<sup>+</sup> T-cells (defined as TCF1<sup>+</sup>PD-1<sup>+</sup>) are essential for the response to anti-PD-1 therapy <sup><xref ref-type="bibr" rid="R20">20</xref>–<xref ref-type="bibr" rid="R24">24</xref></sup> and are thought to be self-renewing precursors of effector T-cells. Further analysis revealed four distinct clusters of intratumoral stem-like CD8<sup>+</sup> T-cells (<xref ref-type="fig" rid="F3">Figure 3D</xref>). Using UCell analysis, we found that cluster 1 had the highest stemness score, closely resembling the previously characterized CD62L<sup>+</sup> stem-like population <sup><xref ref-type="bibr" rid="R35">35</xref></sup>. Cluster 3 showed a strong proliferation signature, displaying high expression of genes associated with the G1S and G2M phases (<xref ref-type="fig" rid="F3">Figure 3E</xref>). While the frequency of stem-like CD8<sup>+</sup> T-cells in cluster 1 remained unchanged, the number of cells in cluster 3 significantly increased among pre-existing intratumoral stem-like CD8<sup>+</sup> T-cells after radiotherapy (<xref ref-type="fig" rid="F3">Figure 3F</xref>). To validate these findings, we applied the same threshold to the G1S and G2M UCell scores for all stem-like CD8<sup>+</sup> T-cells. This analysis confirmed that the frequency of proliferating stem-like CD8<sup>+</sup> T-cells was indeed higher in pre-existing intratumoral CD8<sup>+</sup> T-cells after radiotherapy (<xref ref-type="fig" rid="F3">Figure 3G</xref>). Moreover, <italic>Mki67</italic> expression was significantly higher after radiotherapy, particularly in pre-existing CD8<sup>+</sup> T-cells (<xref ref-type="fig" rid="F3">Figure 3H</xref>). Together, these data suggest that pre-existing intratumoral stem-like CD8<sup>+</sup> T-cells proliferate in response to radiotherapy.</p><p id="P13">After observing dynamic changes in subsets of intratumoral CD8<sup>+</sup> T-cells following radiotherapy, we aimed to identify the differentiation trajectory of these cells using the Monocle 3 package <sup><xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R37">37</xref></sup>. We selected a root node from the TCF-1<sup>high</sup>, CD62L<sup>high</sup>, and PD-1<sup>low</sup> region (<xref ref-type="supplementary-material" rid="SD1">Figure S10A</xref>). The inferred trajectory was plotted on a UMAP, both for annotated clusters (left) and pseudotime (right), further confirming that exhausted CD8<sup>+</sup> T-cells represent the most differentiated cell state compared to the naïve-like state (<xref ref-type="supplementary-material" rid="SD1">Figure S10B</xref>). The expression of key differentiation and activation markers along the pseudotime trajectory confirmed that pseudotime accurately reflects the biological differentiation states of CD8<sup>+</sup> T-cells. For example, CD62L and TCF-1 expression progressively decrease over pseudotime, while PD-1 and TIM-3 increase in expression (<xref ref-type="supplementary-material" rid="SD1">Figure S10C</xref>). Trajectory inference also identified three gray nodes as different outcomes of the trajectory within the stem-like CD8<sup>+</sup> T-cell population, which are directly linked to the exhausted and effector/memory states. This suggests that intratumoral stem-like CD8<sup>+</sup> T-cells may indeed be precursors of differentiated CD8<sup>+</sup> T-cells in response to radiotherapy.</p></sec><sec id="S7"><title>TCF-1<sup>+</sup> cells are essential for the efficacy of radiotherapy</title><p id="P14">To evaluate the importance of TCF-1+PD-1<sup>+</sup> stem-like CD8<sup>+</sup> T-cells, we used the <italic>Tcf7</italic><sup>DTR-GFP</sup> mouse model to selectively deplete TCF-1<sup>+</sup> cells using diphtheria toxin (DTX) <sup><xref ref-type="bibr" rid="R20">20</xref></sup>. To avoid systemic depletion of TCF-1<sup>+</sup> cells, Thy1.1<sup>+</sup> <italic>Tcf7</italic><sup>DTR-GFP</sup> donor bone marrow was transplanted into lethally irradiated Thy1.2<sup>+</sup> C57BL/6 recipient mice. The remaining host T-cells <sup><xref ref-type="bibr" rid="R38">38</xref>,<xref ref-type="bibr" rid="R39">39</xref></sup> (<xref ref-type="supplementary-material" rid="SD1">Figure S11A</xref>) were depleted by anti-Thy1.2 antibodies (<xref ref-type="supplementary-material" rid="SD1">Figure S11B</xref>). After reconstitution, mice received radiotherapy (or not) and DTX (or not), and all groups received FTY720 (<xref ref-type="fig" rid="F4">Figures 4A</xref> and <xref ref-type="supplementary-material" rid="SD1">S11C</xref>). At the endpoint, we confirmed TCF-1<sup>+</sup> cell depletion by assessing GFP<sup>+</sup> expression in CD8<sup>+</sup> T-cells from the spleen (<xref ref-type="supplementary-material" rid="SD1">Figure S11D</xref>) and the tumor (<xref ref-type="supplementary-material" rid="SD1">Figure S11E</xref>).</p><p id="P15">Radiotherapy decreased tumor progression and weight, and this effect was slightly diminished when TCF-1<sup>+</sup> cells were depleted (<xref ref-type="fig" rid="F4">Figures 4B and 4C</xref>). We also observed the expected increase in CD8<sup>+</sup> T-cell counts after radiotherapy, which was significantly reduced after TCF-1<sup>+</sup> cell depletion (<xref ref-type="fig" rid="F4">Figure 4D</xref>). In line with our previous observations, the number of differentiated (<xref ref-type="fig" rid="F4">Figure 4E</xref>), cytotoxic, SIINFEKL-specific, p15E-specific <sup><xref ref-type="bibr" rid="R40">40</xref></sup>, and proliferating CD8<sup>+</sup> T-cells was significantly higher after radiotherapy, but this increase was limited after TCF-1<sup>+</sup> cell depletion (<xref ref-type="fig" rid="F4">Figure 4F</xref>). These findings suggest that TCF-1<sup>+</sup> cells are precursors of proliferating and differentiating T-cells in the tumor. UMAP analysis confirmed that the radiotherapy-induced changes in pre-existing intratumoral CD8<sup>+</sup> T-cells depend on TCF-1<sup>+</sup> cells (<xref ref-type="supplementary-material" rid="SD1">Figure S12</xref>). Furthermore, the increase in the number of SIINFEKL-specific (cluster 4) and Ki-67<sup>high</sup> (cluster 6) CD8<sup>+</sup> T-cells depends on TCF-1<sup>+</sup> cells (<xref ref-type="supplementary-material" rid="SD1">Figures S12B and S12C</xref>).</p><p id="P16">To corroborate these findings and examine the role of stem-like CD8<sup>+</sup> T-cells in longterm radiotherapy-induced tumor control, we conducted the TCF-1<sup>+</sup> depletion experiment with a focus on survival (<xref ref-type="supplementary-material" rid="SD1">Figure S13A</xref>). We generated Thy1.1<sup>+</sup> <italic>Tcf7</italic><sup>DTR-GFP</sup>→Thy1.2<sup>+</sup> <italic>Tcrb</italic><sup>-/-</sup> <sup><xref ref-type="bibr" rid="R41">41</xref></sup> bone marrow chimeras, which circumvented the need to deplete host T-cells (<xref ref-type="supplementary-material" rid="SD1">Figures S13B</xref>). We treated all groups with FTY720 to block new T-cell infiltration (<xref ref-type="supplementary-material" rid="SD1">Figure S13C</xref>) and validated TCF-1<sup>+</sup> cell depletion by analyzing GFP<sup>+</sup> expression in CD8<sup>+</sup> T-cells from the spleen at the time of sacrifice (<xref ref-type="supplementary-material" rid="SD1">Figure S13D</xref>). We monitored the tumors for 50 days and observed a significant tumor control following radiotherapy, but this effect was reduced after TCF-1<sup>+</sup> cell depletion (<xref ref-type="supplementary-material" rid="SD1">Figure S13E</xref>).</p><p id="P17">Although no significant change in survival was observed due to biological variation (<xref ref-type="supplementary-material" rid="SD1">Figure S13F</xref>), we found a decreased proportion of mice responding to radiotherapy after TCF-1<sup>+</sup> depletion (<xref ref-type="supplementary-material" rid="SD1">Figure S13G</xref>). These observations suggest that TCF-1<sup>+</sup> cells play a crucial role in radiotherapy-induced immunological and clinical response.</p></sec><sec id="S8"><title>Stem-like CD8<sup>+</sup> T-cells differentiate and proliferate after radiotherapy</title><p id="P18">To investigate whether stem-like CD8<sup>+</sup> T-cells are the precursors of radiotherapy-induced effector CD8<sup>+</sup> T-cells, we sorted intratumoral TCF-1<sup>-</sup>PD-1<sup>+</sup> (effector) and TCF-1<sup>+</sup>PD-1<sup>+</sup> (stem-like) CD8<sup>+</sup> T-cells (<xref ref-type="supplementary-material" rid="SD1">Figure S14</xref>) and adoptively transferred 3,000 sorted CD8<sup>+</sup> T-cells (CD45.1) into tumor-bearing <italic>Tcrb</italic><sup>-/-</sup> mice. Mice received radiotherapy one day later, and CD8<sup>+</sup> T-cells from the tumor and tumor-draining lymph nodes were analyzed nine days after radiotherapy (<xref ref-type="fig" rid="F5">Figure 5A</xref>). Tumor size and weight did not significantly differ between mice injected with stem-like or effector CD8<sup>+</sup> T-cells (<xref ref-type="fig" rid="F5">Figures 5B and 5C</xref>). However, six days after radiotherapy we found a significantly higher frequency of CD45.1<sup>+</sup> CD8<sup>+</sup> T-cells in the blood of mice injected with stem-like CD8<sup>+</sup> T-cells (<xref ref-type="fig" rid="F5">Figure 5D</xref>). Similarly, mice injected with stem-like CD8<sup>+</sup> T-cells showed significantly higher counts of CD8<sup>+</sup> T-cells in both the tumor (<xref ref-type="fig" rid="F5">Figure 5E</xref>) and the tumor-draining lymph nodes (<xref ref-type="fig" rid="F5">Figure 5F</xref>). UMAP analysis of stem-like CD8<sup>+</sup> T-cell recipient mice revealed distinct clustering and phenotypic differences in CD8<sup>+</sup> T-cells collected from tumors and lymph nodes (<xref ref-type="supplementary-material" rid="SD1">Figure S15A and S15B</xref>). In the lymph nodes, most CD8<sup>+</sup> T-cells maintained a less differentiated phenotype (TCF-1<sup>high</sup> PD-1<sup>low</sup>), whereas intratumoral CD8<sup>+</sup> T-cells showed a more differentiated phenotype (TCF-1<sup>low</sup> PD-1<sup>high</sup>) (<xref ref-type="supplementary-material" rid="SD1">Figures S15A and S15B</xref>). Early differentiated clusters, such as cluster 1 (PD-1<sup>low</sup>TIM-3<sup>low</sup>), were significantly more frequent in the lymph nodes, while more differentiated clusters, like cluster 4 (PD-1<sup>high</sup>TIM-3<sup>high</sup>), were significantly higher in the tumor (<xref ref-type="supplementary-material" rid="SD1">Figures S15C and S15D</xref>). These results suggest that stem-like CD8<sup>+</sup> T-cells preserve their stemness in the lymph nodes but differentiate and proliferate upon reaching the tumor microenvironment.</p><p id="P19">To further validate these findings and confirm that radiotherapy is essential for the stem-like CD8<sup>+</sup> T-cell response, we conducted a similar experiment including untreated controls. This time, <italic>Tcrb</italic><sup>-/-</sup> mice received 1,000 sorted cells (<xref ref-type="supplementary-material" rid="SD1">Figure S16A</xref>). Unlike in the previous experiment, we detected few transferred cells in the blood six days after radiotherapy, suggesting that 1,000 cells might be insufficient for detection in circulation (<xref ref-type="supplementary-material" rid="SD1">Figure S16B</xref>). We observed radiotherapy-induced tumor control independent of whether stem-like or effector CD8<sup>+</sup> T-cells were transferred (<xref ref-type="supplementary-material" rid="SD1">Figures S16C and S16D</xref>). However, despite the lower cell count, radiotherapy significantly increased CD8<sup>+</sup> T-cell count in the lymph nodes (<xref ref-type="supplementary-material" rid="SD1">Figure S16E</xref>) and the tumor (<xref ref-type="supplementary-material" rid="SD1">Figure S16F</xref>) in mice that received stem-like CD8<sup>+</sup> T-cells. Together, these findings suggest that stem-like CD8<sup>+</sup> T-cells proliferate and differentiate into effectors in response to radiotherapy, and as such play a crucial role in radiotherapy-induced tumor control by serving as precursors to effector CD8<sup>+</sup> T-cells.</p></sec></sec><sec id="S9" sec-type="discussion"><title>Discussion</title><p id="P20">Radiotherapy enhances the infiltration of CD8<sup>+</sup> T-cells and other immune cells into the tumor microenvironment, promoting their differentiation and activation <sup><xref ref-type="bibr" rid="R5">5</xref>–<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R30">30</xref></sup>. However, the temporal dynamics of these changes, particularly in pre-existing intratumoral CD8<sup>+</sup> T-cells, have not been fully explored. We found that radiotherapy-induced tumor control was independent of <italic>de novo</italic> recruited CD8<sup>+</sup> T-cells. This finding is consistent with a previous study <sup><xref ref-type="bibr" rid="R32">32</xref></sup> and implies two key points; some pre-existing intratumoral CD8<sup>+</sup> T-cells are radioresistant, and radiotherapy promotes the proliferation and differentiation of these radioresistant CD8<sup>+</sup> T-cells. One day after radiotherapy, we observed a decrease in the number of pre-existing intratumoral CD8<sup>+</sup> T-cells, particularly of the proliferating fraction. Although intratumoral CD8<sup>+</sup> T-cells are generally considered more radioresistant compared to other tissues, such as the lymphoid organs<sup><xref ref-type="bibr" rid="R32">32</xref></sup>, it has been reported that proliferating CD8<sup>+</sup> T-cells are more sensitive to radiotherapy-induced cell death <sup><xref ref-type="bibr" rid="R42">42</xref></sup>. Supported by previous studies <sup><xref ref-type="bibr" rid="R32">32</xref></sup>,<sup><xref ref-type="bibr" rid="R43">43</xref></sup>, some pre-existing intratumoral CD8<sup>+</sup> T-cells survive after radiotherapy. The surviving cells demonstrated a proliferative response, peaking six days after radiotherapy. We depleted TCF-1<sup>+</sup> precursors to assess their role and found that, in their absence, radiotherapy-induced tumor control and CD8<sup>+</sup> T-cell expansion were significantly impaired but not completely abrogated. This suggests that TCF-1<sup>+</sup> cells, including stem-like CD8<sup>+</sup> T-cells, are crucial for radiotherapy response, though TCF-1<sup>-</sup> CD8<sup>+</sup> T-cells also contribute to tumor control. This fits with previous work showing that differentiated CD8<sup>+</sup> T-cells contributed to the response to PD-1 blockade <sup><xref ref-type="bibr" rid="R44">44</xref>–<xref ref-type="bibr" rid="R46">46</xref></sup>. Thus, while different subsets of CD8<sup>+</sup> T-cells contribute to the efficacy of radiotherapy, we demonstrated that the small population of intratumoral stem-like CD8<sup>+</sup> T-cells is indispensable for an effective response. The adoptive transfer of intratumoral stem-like CD8<sup>+</sup> T-cells further validated their importance for radiotherapy response. These transferred stem-like CD8<sup>+</sup> T-cells differentiated and proliferated in response to radiotherapy within the tumor. Taken together, by showing that intratumoral stem-like CD8<sup>+</sup> T-cells are precursors to radiotherapy-induced protective effector cells, we identified the mechanism explaining why irradiated tumors contain more effector CD8<sup>+</sup> T-cells.</p><p id="P21">We showed that pre-existing intratumoral CD8<sup>+</sup> T-cells can drive an effective radiotherapy response during the initial phase, resulting in the differentiation of CD8<sup>+</sup> T-cells in the tumor. For example, adoptively transferred stem-like CD8<sup>+</sup> T-cells preserved their stemness in the tumor-draining lymph node, whereas in response to radiotherapy they rapidly differentiated into effector cells in the tumor. This finding aligns with previous work showing that lymph nodes are reservoirs for stem-like CD8<sup>+</sup> T-cells that migrate into tumors, differentiate locally, and help restrict tumor progression <sup><xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R47">47</xref></sup>. Our sequencing results confirm this process, showing that intratumoral CD8<sup>+</sup> T-cells acquired a more differentiated phenotype after radiotherapy. The differentiation was even more pronounced when <italic>de novo</italic> infiltration was blocked. This suggests that while pre-existing intratumoral CD8<sup>+</sup> T-cells are sufficient for immediate responses, continued recruitment from lymph nodes may be essential for long-term anti-tumor response. PD-1/PD-L1 blockade synergizes with radiotherapy as shown in preclinical models <sup><xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R43">43</xref></sup>; therefore, this combination is currently explored in cancer patients <sup><xref ref-type="bibr" rid="R48">48</xref>–<xref ref-type="bibr" rid="R52">52</xref></sup> with promising results <sup><xref ref-type="bibr" rid="R53">53</xref></sup>. Stem-like CD8<sup>+</sup> T-cells (TCF1<sup>+</sup> PD-1<sup>+</sup>) are crucial for the response to anti-PD-1 therapy by serving as a reservoir for effector T-cells <sup><xref ref-type="bibr" rid="R20">20</xref>–<xref ref-type="bibr" rid="R24">24</xref></sup>. Our data suggest that stem-like CD8<sup>+</sup> T-cells play a similar role in the response to radiotherapy, potentially explaining the synergy seen after combining both treatments <sup><xref ref-type="bibr" rid="R54">54</xref></sup>.</p><p id="P22">In conclusion, we demonstrated that radiotherapy promotes the proliferation and differentiation of pre-existing intratumoral CD8<sup>+</sup> T-cells, including stem-like CD8<sup>+</sup> T-cells.</p><p id="P23">This process is required and sufficient for therapeutic efficacy during the initial phase, while sustained anti-tumor response may require the recruitment of stem-like CD8<sup>+</sup> T-cells from the tumor-draining lymph nodes.</p><sec id="S10"><title>Limitation of the study</title><p id="P24">One limitation of this study is the use of a single 20 Gy radiotherapy dose. While similar transcriptional changes and CD8<sup>+</sup> T-cell activation have been observed between 5 Gy, 10 Gy, and 20 Gy doses <sup><xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref></sup>, the effects of varying radiation doses on our findings still need to be explored. Additionally, single high-dose radiotherapy may not fully capture the effects of fractionated radiotherapy commonly used in clinical settings. Fractionation is known to influence immune responses, including CD8<sup>+</sup> T-cell dynamics, even when the biologically effective dose is equivalent <sup><xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R30">30</xref>,<xref ref-type="bibr" rid="R43">43</xref>,<xref ref-type="bibr" rid="R55">55</xref>,<xref ref-type="bibr" rid="R56">56</xref></sup>. Inherently, it is also challenging to compare single-dose and fractionated radiotherapy because the timing of the treatments differs, making it difficult to align observations and assess immune responses consistently. Future studies are needed to determine how much of our findings also apply to fractionated treatments. This study exclusively uses murine tumor models, and since the tumor microenvironment and immune interactions in humans may differ, the clinical applicability of our observations requires further investigation. Although we validated some of our observations in an orthotopic B16-OVA model, the majority of the study utilized non-orthotopic, subcutaneous models (LLC and MC38). While subcutaneous models were practical for tumor localization and measurement, they do not fully replicate the physiological conditions of orthotopic tumors <sup><xref ref-type="bibr" rid="R57">57</xref>,<xref ref-type="bibr" rid="R58">58</xref></sup>. Further studies are needed to confirm how much of these observations extend to other orthotopic models.</p></sec></sec><sec sec-type="methods" id="S11" specific-use="web-only"><title>Star Methods</title><sec id="S12"><title>Resource Availability</title><sec id="S13"><title>Lead contact</title><p id="P25">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Maries van den Broek (<email>vandenbroek@immunology.uzh.ch</email>).</p></sec><sec id="S14"><title>Materials availability</title><p id="P26">The materials generated for this study can be provided upon reasonable request.</p></sec></sec><sec id="S15"><title>Experimental Model Details</title><sec id="S16"><title>Mice</title><p id="P27">C57BL/6NRj mice were purchased from Janvier Labs. <italic>Tcf7</italic><sup>DTR-GFP</sup> mice <sup><xref ref-type="bibr" rid="R22">22</xref></sup> were provided by Werner Held (University of Lausanne). IgHaThy1.1 (B6.Cg-Gpi1a Thy1a Igha) <sup><xref ref-type="bibr" rid="R59">59</xref>–<xref ref-type="bibr" rid="R61">61</xref></sup> mice were provided by Nicole Joller (University of Zurich). <italic>Tcf7</italic><sup>DTR-GFP</sup> x IgHaThy1.1 and <italic>Tcf7</italic><sup>DTR-GFP</sup> x OT-I <sup><xref ref-type="bibr" rid="R62">62</xref></sup> x Ly5.1 mice were bred in-house. <italic>Tcrb</italic><sup>-/-</sup> (B6.129P2-<italic>Tcrb<sup>tm1Mom</sup></italic>/J) <sup><xref ref-type="bibr" rid="R41">41</xref></sup> mice were provided by Annette Oxenius (ETH Zurich, Switzerland). All strains have a C57BL/6 background. Breeding and experiments were performed under specific pathogen-free (SPF) conditions in facilities of the Laboratory Animal Services Center (LASC) at the University of Zurich. Mice had access to food and water containing 0.5 ppm ClO<sub>2</sub> <italic>ad libitum</italic> and were kept in a 12-hour light/dark cycle. Experiments were performed using female mice aged 8-12 weeks unless otherwise stated. All procedures were approved by the Cantonal Veterinary Office Zurich under licenses ZH170/2021 and ZH38/2021.</p></sec><sec id="S17"><title>Cell lines and cell culture</title><p id="P28">MC38 colon adenocarcinoma was obtained from Kerafast, LLC and B16F10 melanoma cells were obtained from ATCC. MC38-OVA-GFP<sup>dim</sup> cells were provided by Mark J. Smyth <sup><xref ref-type="bibr" rid="R63">63</xref></sup>,QIMR Berghofer Medical Research Institute, Brisbane, Australia). B16F10 and LLC cells were lentivirally transduced to express OVA using the pHR OVA/p2a/mCherry-CaaX plasmid (Addgene #113030). Six days after transduction, cells were sorted for live (Zombie NIR<sup>–</sup>) mCherry<sup>+</sup> cells. Cancer cells were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco), 100 U/mL penicillin, 100 μg/mL streptomycin (Sigma), and 2 mM L-glutamine (Gibco) at 37°C in a humidified atmosphere with 5% CO2. Cell lines were tested negative for <italic>Mycoplasma</italic> ssp. by PCR. Cells were also tested negative for 18 additional mouse pathogens using the IMPACT II Test (IDEXX Bioanalytics).</p></sec></sec><sec id="S18"><title>Method Details</title><sec id="S19"><title><italic>In vivo</italic> experiments</title><sec id="S20"><title>Cancer cell injection</title><p id="P29">Cultured cancer cells were harvested and suspended in a 2:1 mixture of PBS and Matrigel Basement Membrane Matrix (Corning). The number of injected cells is specified in the figure legends. Hundred μl of the cell suspension was injected subcutaneously (s.c.) into the shaved right flank. For survival studies, mice were euthanized at the humane endpoint, i.e., when tumor size reached 150 mm<sup>2</sup> or the tumor developed an invagination &gt; 30% of its surface.</p></sec><sec id="S21"><title>Depletion of cells</title><p id="P30">To deplete T-cells, mice received two injections of 500 μg of CD4-depleting antibody (clone GK1.5; Rat IgG2a) or CD8-depleting antibody (clone YTS169.4; Rat IgG2a) intraperitoneally (i.p.) at days -1 and +12 relative to radiotherapy. T-cell depletion was confirmed by flow cytometric analysis of blood taken two days after the first injection.</p><p id="P31">To deplete the remaining host T-cells from Thy1.1<sup>+</sup> <italic>Tcf7</italic><sup>DTR-GFP</sup>→Thy1.2<sup>+</sup> C57BL/6 bone marrow chimeras, 500 μg of Thy1.2-depleting antibody (clone 30H12; Rat IgG2b) was injected i.p. on day -1 before tumor cell injection and on day -1 relative to radiotherapy. Depletion was verified by flow cytometry analysis of blood samples.</p><p id="P32">To deplete TCF-1 expressing cells in <italic>Tcf7</italic><sup>DTR-GFP</sup> mice, 250 ng of diphtheria toxin (DTX) was injected i.p. twice a week, starting one day before radiotherapy. Depletion was monitored by analyzing blood samples during the experiment and confirmed at the endpoint in the spleen and tumor tissues using flow cytometry.</p></sec><sec id="S22"><title>FTY720 administration</title><p id="P33">FTY720 (Sigma-Aldrich) was administered <italic>per os</italic> by micropipette-guided drug administration (MDA), as previously described <sup><xref ref-type="bibr" rid="R64">64</xref></sup>. Mice received 20 μg FTY720 diluted in 80 μL condensed milk (diluted 1:2 with sterile water). The reduction of circulating lymphocytes was confirmed by analyzing blood samples using flow cytometry.</p></sec><sec id="S23"><title>Adoptive transfer of T-cells</title><p id="P34">For adoptive cell transfer, CD8<sup>+</sup> T-cells were isolated from the spleens of age-matched OT-I mice using the EasySep Mouse CD8<sup>+</sup> T-Cell Isolation Kit (STEMCELL Technologies) according to the manufacturer’s instructions. The purity of the enriched CD8<sup>+</sup> T-cells (&gt; 95%) was verified by flow cytometry. Purified CD8<sup>+</sup> T-cells were injected into recipient mice via the lateral tail vein in 200 μL of sterile PBS. The number of transferred cells is specified in the figure legends.</p></sec><sec id="S24"><title>Radiotherapy</title><p id="P35">Tumor-bearing mice were randomized based on tumor size immediately before radiotherapy. Radiotherapy was performed as described <sup><xref ref-type="bibr" rid="R6">6</xref></sup>. Briefly, mice were anesthetized by i.p. injection of 50 mg/kg ketamine and 10 mg/kg xylazine. Vitamin A eye ointment was applied to the eyes to prevent dryness during the procedure. Mice were secured in a lead cage to ensure localized irradiation of the tumor with a single dose of 20 Gy using an RS-2000 irradiation unit (Rad Source) with a dose rate of 1.81 Gy/min.</p></sec><sec id="S25"><title>Bone Marrow Chimeras</title><p id="P36">C57BL/6NRj mice underwent total body irradiation given as two doses of 5.5 Gy irradiation, administered 6 hours apart. Following the first dose, mice received 0.1% Borgal (MSD Animal Health) in the drinking water for 2 weeks. One day after irradiation, bone marrow from <italic>Tcf7</italic><sup>DTR-GFP</sup> donor mice was harvested by flushing the tibiae and femora with 2.2 mL of sterile PBS. Mice were given approximately 10<sup>6</sup> bone marrow cells i.v. Reconstitution was confirmed 8 weeks later by flow cytometric analysis of the blood. Chimeras were rested at least 8 weeks before use in experiments.</p></sec></sec></sec><sec id="S26"><title>Tissue collection and processing</title><p id="P37">Tumors, tumor-draining lymph nodes (tdLNs) and spleens were excised and placed in RPMI medium supplemented with 10% FCS. Tumors were manually minced into small fragments and digested in RPMI containing 10% FCS, 1 mg/mL collagenase IV (Thermo Fisher Scientific), and 50 μg/mL DNase I (Roche) for 45 minutes at 37°C on a rotating platform. Digestion was stopped by the addition of 5 mL of ice-cold PBS. The digested tumor material was passed through a 70-μm cell strainer using the plunger of a 5-mL syringe. Cells were washed with PBS and pelleted by centrifugation at 350 <italic>g</italic> for 5 minutes. Red blood cells were lysed with RBC lysis buffer (17 mM Tris, pH 7.2, and 144 mM NH4Cl) for 2 minutes at room temperature. Spleens and tdLNs were passed through a 70-μm cell strainer without enzymatic digestion and washed with complete RPMI. Blood samples were collected via submental bleeding into PBS containing 2 mM EDTA.</p></sec><sec id="S27"><title>Flow Cytometry</title><p id="P38">Single-cell suspensions were incubated with anti-CD16/32 antibody in PBS for 5 minutes to block Fc receptors. Surface marker staining was performed by incubating cells with 50 μL of an antibody mixture in PBS for 30 minutes at 4°C. For intracellular staining, cells were fixed and permeabilized using the Foxp3/Transcription Factor Staining Buffer Set (Invitrogen) according to the manufacturer’s instructions. Cells were incubated with the intracellular antibody mix prepared in 1X permeabilization buffer and stained in 50 μL volumes overnight at 4°C. After staining, all samples were washed once with permeabilization buffer and once with PBS before acquisition.</p><p id="P39">For experiments involving GFP as a reporter for TCF-1 expression, samples were split in two: One part was used for surface marker staining, and the other part for intracellular staining including fixation and permeabilization.</p><p id="P40">Stained samples were acquired on a Cytek Aurora 5L spectral flow cytometer for high-dimensional analysis or a CyAn ADP flow cytometer for panels of up to four colors. FCS files were analyzed using FlowJo software version 10.10.0. Data from gated populations of interest were exported as compensated FCS files and further processed in R version 4.3.2.</p><p id="P41">Preprocessed FCS files were arcSinh transformed, and raw marker intensities were quantile normalized to ensure comparability across samples. Data were visualized using Uniform Manifold Approximation and Projection (UMAP) <sup><xref ref-type="bibr" rid="R65">65</xref></sup>, and unsupervised clustering was performed using RPhenograph <sup><xref ref-type="bibr" rid="R66">66</xref></sup>. Data visualization and statistical analyses were conducted using the ggplot2 package in R, with Bioconductor version 3.17 used for further analysis.</p></sec><sec id="S28"><title>Single-Cell RNA Sequencing</title><p id="P42">Single-cell suspensions were prepared from individual tumor samples (n = 8 per condition). Cells were labeled using the BD Single-Cell Multiplexing Kit and pooled according to their respective experimental conditions.</p><p id="P43">Intratumoral CD8<sup>+</sup> T-cells were isolated as single, live, CD45<sup>+</sup>, CD8<sup>+</sup> cells using a BD FACSAria III cell sorter. A total of 40,000 cells were loaded onto a BD Rhapsody cartridge and processed for cDNA synthesis following the BD Rhapsody Single-Cell Capture and cDNA Synthesis protocol (Doc ID: 23-22951(01)). Library amplification was performed using the BD Rhapsody System mRNA Whole Transcriptome Analysis (WTA) and Sample Tag Library Preparation Protocol (Doc ID: 23-24119(02)).</p><p id="P44">Sequencing was carried out on an Illumina NovaSeq 6000 or NovaSeq X Plus platform using 150 bp paired-end reads (R1 = 51 cycles, R2 = 71 cycles), with an average sequencing depth of approximately 50,000 reads per cell. Data processing, including read alignment, cell barcode demultiplexing, read deduplication, expression matrix generation, and quality reporting, was performed using the Rhapsody Sequence Analysis Pipeline v2.0.</p><p id="P45">Further downstream analysis of expression matrices was performed in R v4.3.2. Cells were filtered to exclude those with more than 10% mitochondrial content or less than 2% ribosomal protein content. Duplicate cells were identified and removed using scDblFinder <sup><xref ref-type="bibr" rid="R67">67</xref></sup>. The Seurat pipeline v5.1 <sup><xref ref-type="bibr" rid="R68">68</xref></sup> was used for normalization, dimensionality reduction, and clustering. CD8<sup>+</sup> T-cell populations and their subsets were annotated using ProjectTILs <sup><xref ref-type="bibr" rid="R33">33</xref></sup> and scGate <sup><xref ref-type="bibr" rid="R69">69</xref></sup>. Gene set enrichment analysis for T-cell programs was performed with the UCell package <sup><xref ref-type="bibr" rid="R34">34</xref></sup>.</p><p id="P46">To investigate cellular trajectories and estimate pseudotime, Monocle 3 <sup><xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R37">37</xref></sup> was used. Cells with the highest expression of <italic>Sell</italic> and <italic>Tcf7</italic> were chosen as the starting point for trajectory inference. Monocle 3 then arranged intratumoral CD8<sup>+</sup> T-cells along a trajectory according to their transcriptional progression, with default settings applied throughout the analysis.</p></sec><sec id="S29"><title>Statistical analysis</title><p id="P47">One-way ANOVA followed by Tukey’s post-hoc test was used to compare three or more groups. For tumor size comparisons, the last time point was used for the one-way ANOVA analysis. For comparisons between two groups, the Mann-Whitney U-test was used. A <italic>p</italic>-value &lt; 0.05 was considered significant. All statistical analyses were performed using GraphPad Prism software (v10.0.0).</p></sec><sec id="S30"><title>Key Resources Table</title><table-wrap id="T1" position="anchor" orientation="portrait"><table frame="box" rules="all"><thead><tr><th align="left" valign="top">REAGENT or RESOURCE</th><th align="left" valign="top">SOURCE</th><th align="left" valign="top">IDENTIFIER</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="3" style="background-color:#EDEDED"><bold>Antibodies</bold></td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD16/32 (clone 93)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#101302 RRID: AB_312801</td></tr><tr><td align="left" valign="top">InVivoMAb anti-mouse Thy1.2 (clone 30H12)</td><td align="left" valign="top">BioXCell</td><td align="left" valign="top">#BE0066 RRID:AB_1107682</td></tr><tr><td align="left" valign="top">Anti-CD4 (clone GK1.5)</td><td align="left" valign="top">BioXCell</td><td align="left" valign="top">#BE0003-1 RRID: AB_1107636</td></tr><tr><td align="left" valign="top">Anti-CD8 (clone YTS 169.4)</td><td align="left" valign="top">BioXCell</td><td align="left" valign="top">#BE0117 RRID: AB_10950145</td></tr><tr><td align="left" valign="top">Rabbit monoclonal anti-TCF1/TCF7-AlexaFluor 647 (clone C63D9)</td><td align="left" valign="top">Cell Signaling Technologies</td><td align="left" valign="top">#6709 RRID: AB_2797631</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD223-BUV395 (clone C9B7W)</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">#745693 RRID: AB_2743177</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti-CD4-BUV496 (clone GK1.5)</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">#612952 RRID: AB_2870684</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD45-BUV563 (clone 30-F11)</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">#612924 RRID: AB_2722550</td></tr><tr><td align="left" valign="top">Syrian Hamster monoclonal anti-KLRG1-BUV615 (clone 2F1)</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">#751191 RRID: AB_2875213</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD11b-BUV661 (clone M1/70)</td><td align="left" valign="top">eBioscience</td><td align="left" valign="top">#367-0112-82 RRID: AB_2869708</td></tr><tr><td align="left" valign="top">Armenian Hamster monoclonal anti-TCRbeta-BUV737 (clone H57-597)</td><td align="left" valign="top">eBioscience</td><td align="left" valign="top">#367-5961-82 RRID: AB_2896026</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD8a-BUV805 (clone 53-6.7)</td><td align="left" valign="top">eBioscience</td><td align="left" valign="top">#368-0081-82 RRID: AB_2896078</td></tr><tr><td align="left" valign="top">H-2K<sup>b</sup>/OVA tetramer-BUV421</td><td align="left" valign="top">Hans Christian Probst (Johannes- Gutenberg- University Mainz, Germany) or NIH Tetramer Core Facility</td><td align="left" valign="top">N/A</td></tr><tr><td align="left" valign="top">H-2K<sup>b</sup>/p15E tetramer-APC</td><td align="left" valign="top">NIH Tetramer Core Facility</td><td align="left" valign="top">N/A</td></tr><tr><td align="left" valign="top">Mouse anti-CD90.1-PB (clone OX/7)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#202522 RRID:AB_1595477</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti-Ki-67-BV480 (clone B56)</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">#566109 RRID: AB_2739511</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD62L-BV570 (clone MEL-14)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#104433 RRID: AB_10900262</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti-CX3CR1-BV605 (clone SA011F11)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#149027 RRID: AB_2565937</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti-CD366-BV650 (clone 5D12)</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">#747623 RRID: AB_2744189</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti-T-bet-BV711 (clone 4B10)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#644820 RRID: AB_2715766</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD279-BV785 (clone 29F.1A12)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#135225 RRID: AB_2563680</td></tr><tr><td align="left" valign="top">Recombinant monoclonal anti-TOX-PE (clone REA473)</td><td align="left" valign="top">Miltenyi Biotec</td><td align="left" valign="top">#130-120-716 RRID: AB_2801785</td></tr><tr><td align="left" valign="top">Armenian hamster monoclonal anti-CD69-PE/Cy5 (clone H1.2F3)</td><td align="left" valign="top">eBioscience</td><td align="left" valign="top">#15-0691-82 RRID: AB_468772</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD44-PE/Cy7 (clone IM7)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#103030 RRID: AB_830787</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-EOMES-PE-eFluor610 (clone Dan11mag)</td><td align="left" valign="top">eBioscience</td><td align="left" valign="top">#61-4875-82 RRID: AB_2574614</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti-CD45.1-PB (clone A20)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#110722 RRID: AB_492866</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti-CD45.2-FITC (clone 104)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#109806 RRID: AB_313443</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti Granzyme B- PerCP/Cyanine5.5 (clone QA16A02)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#372212 RRID: AB_2728379</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti-CD39-PerCP-eFluor 710 (clone 24DMS1)</td><td align="left" valign="top">eBioscience</td><td align="left" valign="top">#46-0391-82 RRID: AB_10717953</td></tr><tr><td align="left" valign="top">Donkey polyclonal anti-rabbit IgG-Alexa Fluor 488</td><td align="left" valign="top">Jackson ImmunoResearch</td><td align="left" valign="top">#711-545-152 RRID: AB_2313584</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti-FoxP3-AlexaFluor488 (clone 150D)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#320012 RRID: AB_439748</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD40-APC (clone 3/23)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#124612 RRID: AB_1134072</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD25-BV650 (clone PC61)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#102038 RRID: AB_2563060</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-F4/80-PE (clone BM8)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#123110 RRID: AB_893486</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-Ly-6G-BV785 (clone 1A8)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#127645 RRID: AB_2566317</td></tr><tr><td align="left" valign="top">Armenian hamster monoclonal anti-CD11c-BV570 (clone N418)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#117331 RRID: AB_10900261</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti-XCR1-BV510 (clone ZET)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#148218 RRID: AB_2565231</td></tr><tr><td align="left" valign="top">Armenian hamster monoclonal anti-CD80-BV605 (clone 16-10A1)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#104729 RRID: AB_11126141</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-Ly-6C-BV711 (clone HK1.4)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#128037 RRID: AB_2562630</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD274-FITC (clone MIH6)</td><td align="left" valign="top">Bio-Rad</td><td align="left" valign="top">#MCA2626F</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD86-PE/Cy5 (clone GL-1)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#105016 RRID: AB_493602</td></tr><tr><td align="left" valign="top">Mouse monoclonal anti-CD45.2-APC (clone 104)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#109814 AB_389211</td></tr><tr><td align="left" valign="top">Rat monoclonal anti-CD70-PE/Cy7 (clone FR70)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">#104612 RRID: AB_2750467</td></tr><tr><td align="left" valign="top" colspan="3" style="background-color:#EDEDED"><bold>Chemicals, peptides, and recombinant proteins</bold></td></tr><tr><td align="left" valign="top">RPMI 1640 medium</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">21875034</td></tr><tr><td align="left" valign="top">Fetal Bovine Serum (FBS)</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">A5256701</td></tr><tr><td align="left" valign="top">Collagenase Type IV</td><td align="left" valign="top">Thermo Fisher Scientific</td><td align="left" valign="top">17104019</td></tr><tr><td align="left" valign="top">DNAse I</td><td align="left" valign="top">Roche</td><td align="left" valign="top">10104159001</td></tr><tr><td align="left" valign="top">DPBS</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">14190144</td></tr><tr><td align="left" valign="top">FTY720</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">SML0700</td></tr><tr><td align="left" valign="top">Diphtheria Toxin (DTX)</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">D0564</td></tr><tr><td align="left" valign="top">0.4% Trypan Blue Solution</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">15250061</td></tr><tr><td align="left" valign="top">Ketanarkon 100 (Ketamin)</td><td align="left" valign="top">Streuli Tiergesundheit AG</td><td align="left" valign="top">QN01AX03</td></tr><tr><td align="left" valign="top">Rompun® 2% (Xylazine)</td><td align="left" valign="top">QN05CM92</td><td align="left" valign="top">Provet AG</td></tr><tr><td align="left" valign="top">Vitamin A Eye Ointment</td><td align="left" valign="top">Bausch + Lomb Swiss AG</td><td align="left" valign="top">N/A</td></tr><tr><td align="left" valign="top">L-Glutamine (200 mM)</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">25030081</td></tr><tr><td align="left" valign="top">Matrigel Basement Membrane Matrix</td><td align="left" valign="top">Corning</td><td align="left" valign="top">354234</td></tr><tr><td align="left" valign="top">DMEM medium</td><td align="left" valign="top">Gibco</td><td align="left" valign="top">11965092</td></tr><tr><td align="left" valign="top">UltraComp eBeads Plus Compensation Beads</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">01-3333-42</td></tr><tr><td align="left" valign="top" colspan="3" style="background-color:#EDEDED"><bold>Experimental models: Organisms/strains</bold></td></tr><tr><td align="left" valign="top">C57BL/6NRj</td><td align="left" valign="top">Janvier</td><td align="left" valign="top">027</td></tr><tr><td align="left" valign="top">Tcrb<sup>-/-</sup> (B6.129P2-<italic>Tcrb<sup>tm1Mom</sup></italic>/J)</td><td align="left" valign="top">Provided by Annette Oxenius</td><td align="left" valign="top">RRID:IMSR_JAX:002118</td></tr><tr><td align="left" valign="top"><italic>Tc7</italic><sup>DTR-GFP</sup></td><td align="left" valign="top">Provided by Werner Held</td><td align="left" valign="top"><sup><xref ref-type="bibr" rid="R22">22</xref></sup></td></tr><tr><td align="left" valign="top">IgHaThy1.1 (B6.Cg-Gpi1a Thy1a Igha)</td><td align="left" valign="top">Provided by Nicole Joller</td><td align="left" valign="top">RRID:IMSR_JAX:001317</td></tr><tr><td align="left" valign="top"><italic>Tcf7</italic><sup>DTR-GFP</sup> x IgHaThy1.1</td><td align="left" valign="top">N/A</td><td align="left" valign="top">This study</td></tr><tr><td align="left" valign="top"><italic>Tcf7</italic><sup>DTR-GFP</sup> x OT-I x Ly5.1</td><td align="left" valign="top">N/A</td><td align="left" valign="top">This study</td></tr><tr><td align="left" valign="top" colspan="3" style="background-color:#EDEDED"><bold>Critical commercial assays</bold></td></tr><tr><td align="left" valign="top">EasySep Mouse CD8<sup>+</sup> T Cell Isolation Kit</td><td align="left" valign="top">Stemcell</td><td align="left" valign="top">19853</td></tr><tr><td align="left" valign="top">Foxp3 / Transcription Factor Staining Buffer Set</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">00-5523-00</td></tr><tr><td align="left" valign="top">Rhapsody Cartridge Kit</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">633733</td></tr><tr><td align="left" valign="top">Rhapsody Enhanced Cartridge Reagent Kit</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">664887</td></tr><tr><td align="left" valign="top">BD Rhapsody cDNA Kit</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">633773</td></tr><tr><td align="left" valign="top">BD Rhapsody WTA Amplification Kit</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">633801</td></tr><tr><td align="left" valign="top">Single-Cell Sample Multiplexing Kit</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">633793</td></tr><tr><td align="left" valign="top" colspan="3" style="background-color:#EDEDED"><bold>Experimental models: Cell Lines</bold></td></tr><tr><td align="left" valign="top">MC38</td><td align="left" valign="top">Kerafast</td><td align="left" valign="top">CVCL_B288</td></tr><tr><td align="left" valign="top">MC38-OVA-GFP<sup>dim</sup></td><td align="left" valign="top">Mark Smyth, Brisbane, Australia Referred to as MC38-OVA-GFP</td><td align="left" valign="top"><sup><xref ref-type="bibr" rid="R63">63</xref></sup></td></tr><tr><td align="left" valign="top">B16F10</td><td align="left" valign="top">ATCC</td><td align="left" valign="top">CRL-6475</td></tr><tr><td align="left" valign="top">B16F10-OVA</td><td align="left" valign="top">in house</td><td align="left" valign="top">N/A</td></tr><tr><td align="left" valign="top">LLC</td><td align="left" valign="top">ATCC</td><td align="left" valign="top">CRL-1642</td></tr><tr><td align="left" valign="top">LLCcGAStetON-OVA-mCherry</td><td align="left" valign="top">In house, Referred to as LLCOVA</td><td align="left" valign="top">N/A</td></tr><tr><td align="left" valign="top" colspan="3" style="background-color:#EDEDED"><bold>Software and algorithms</bold></td></tr><tr><td align="left" valign="top">FlowJo (v10.9.0)</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com">https://www.flowjo.com</ext-link></td></tr><tr><td align="left" valign="top">GraphPad Prism (v9.5.0)</td><td align="left" valign="top">GraphPad</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link></td></tr><tr><td align="left" valign="top">R (v4.2.2)</td><td align="left" valign="top">R Foundation for Statistical Computing</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></td></tr><tr><td align="left" valign="top">RStudio (v2022.12.0)</td><td align="left" valign="top">Posit, PBC</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://posit.co/download/rstudio/">https://posit.co/download/rstudio/</ext-link></td></tr><tr><td align="left" valign="top" colspan="3" style="background-color:#EDEDED"><bold>Other</bold></td></tr><tr><td align="left" valign="top">FACS Aria III cell sorter</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">N/A</td></tr><tr><td align="left" valign="top">CyAn ADP</td><td align="left" valign="top">Beckman Coulter</td><td align="left" valign="top">N/A</td></tr><tr><td align="left" valign="top">Aurora 5L</td><td align="left" valign="top">Cytek Biosciences</td><td align="left" valign="top">N/A</td></tr><tr><td align="left" valign="top">RS 2000 Small Animal Irradiator</td><td align="left" valign="top">Rad Source Technologies</td><td align="left" valign="top">N/A</td></tr><tr><td align="left" valign="top">70-μm Cell Strainers</td><td align="left" valign="top">Biologix</td><td align="left" valign="top">15-1070-2</td></tr><tr><td align="left" valign="top">Insulin syringe 0.5 mL</td><td align="left" valign="top">Braun</td><td align="left" valign="top">9151125S</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplemental Information</label><media xlink:href="EMS199535-supplement-Supplemental_Information.pdf" mimetype="application" mime-subtype="pdf" id="d110aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S31"><title>Acknowledgments</title><p>This work was supported by the University Research Priority Program “Translational Cancer Research” (University of Zurich; MvdB), the University of Zurich Forschungkredit (HK), the Hartmann-Müller Foundation Zurich (HK, MvdB), the Swiss National Science Foundation (310030_208145 MvdB), the Stiftung für Krebsbekämpfung Zurich (MvdB), the Zurich Cancer League (HK), the Stiftung für medizinische Forschung an der Medizinischen Fakultät der UZH (HK), the Monique Dornonville de la Court Foundation (MvdB). The authors thank the personnel of the Laboratory Animal Services Center (LASC, University of Zurich), particularly Jan Jerzyk, for expert animal care. We thank Tatiane Gorski (Cytometry Facility, University of Zurich) and Hubert Rehrauer (Functional Genomic Center Zurich) for help with scRNA-sequencing.</p></ack><sec id="S32" sec-type="data-availability"><title>Data availability</title><p id="P48">All relevant data supporting the findings of this study are provided in the Methods section. Detailed information on mouse models, reagents, and software used in the research is also described in the Methods.</p></sec><fn-group><fn id="FN1" fn-type="con"><p id="P49"><bold>Author contributions</bold></p><p id="P50">HK and MvdB conceived the experiments and wrote the manuscript; HK, MH, NR and NEB performed the experiments. PP and VC performed sorting. HK, MH, MN and CB analyzed the data. MvdB and HK secured funding; All the authors reviewed the results and approved the final manuscript.</p></fn><fn id="FN2" fn-type="conflict"><p id="P51"><bold>Declaration of interests</bold></p><p id="P52">The authors declare no competing interests.</p></fn><fn id="FN3"><p id="P53"><bold>Ethical approval statement</bold></p><p id="P54">Mouse experiments were performed according to Swiss cantonal and federal regulations on animal protection and approved by the cantonal veterinary office of Zurich under license numbers 38/2021 (33443) and 170/2021 (34178).</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion</article-title><source>Science</source><year>2011</year><volume>331</volume><fpage>1565</fpage><lpage>1570</lpage><pub-id pub-id-type="pmid">21436444</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Pages</surname><given-names>F</given-names></name><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Prognostic and predictive impact of intra- and peritumoral immune infiltrates</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>5601</fpage><lpage>5605</lpage><pub-id pub-id-type="pmid">21846822</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>Dissecting the mechanisms of immune checkpoint therapy</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><fpage>75</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">31925406</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baskar</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>KA</given-names></name><name><surname>Yeo</surname><given-names>R</given-names></name><name><surname>Yeoh</surname><given-names>KW</given-names></name></person-group><article-title>Cancer and radiation therapy: current advances and future directions</article-title><source>Int J Med Sci</source><year>2012</year><volume>9</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="pmcid">PMC3298009</pub-id><pub-id pub-id-type="pmid">22408567</pub-id><pub-id pub-id-type="doi">10.7150/ijms.3635</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Probst</surname><given-names>HC</given-names></name><name><surname>Vuong</surname><given-names>V</given-names></name><name><surname>Landshammer</surname><given-names>A</given-names></name><name><surname>Muth</surname><given-names>S</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Schwendener</surname><given-names>R</given-names></name><name><surname>Pruschy</surname><given-names>M</given-names></name><name><surname>Knuth</surname><given-names>A</given-names></name><name><surname>van den Broek</surname><given-names>M</given-names></name></person-group><article-title>Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation</article-title><source>J Immunol</source><year>2012</year><volume>189</volume><fpage>558</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">22685313</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surace</surname><given-names>L</given-names></name><name><surname>Lysenko</surname><given-names>V</given-names></name><name><surname>Fontana</surname><given-names>AO</given-names></name><name><surname>Cecconi</surname><given-names>V</given-names></name><name><surname>Janssen</surname><given-names>H</given-names></name><name><surname>Bicvic</surname><given-names>A</given-names></name><name><surname>Okoniewski</surname><given-names>M</given-names></name><name><surname>Pruschy</surname><given-names>M</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Neefjes</surname><given-names>J</given-names></name><etal/></person-group><article-title>Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response</article-title><source>Immunity</source><year>2015</year><volume>42</volume><fpage>767</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">25888260</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schadt</surname><given-names>L</given-names></name><name><surname>Sparano</surname><given-names>C</given-names></name><name><surname>Schweiger</surname><given-names>NA</given-names></name><name><surname>Silina</surname><given-names>K</given-names></name><name><surname>Cecconi</surname><given-names>V</given-names></name><name><surname>Lucchiari</surname><given-names>G</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Guggisberg</surname><given-names>E</given-names></name><name><surname>Saba</surname><given-names>S</given-names></name><name><surname>Nascakova</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity</article-title><source>Cell Rep</source><year>2019</year><volume>29</volume><fpage>1236</fpage><lpage>1248</lpage><elocation-id>e1237</elocation-id><pub-id pub-id-type="pmid">31665636</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnette</surname><given-names>BC</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Chlewicki</surname><given-names>L</given-names></name><name><surname>Khodarev</surname><given-names>NN</given-names></name><name><surname>Weichselbaum</surname><given-names>RR</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name><name><surname>Auh</surname><given-names>SL</given-names></name></person-group><article-title>The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>2488</fpage><lpage>2496</lpage><pub-id pub-id-type="pmcid">PMC3070872</pub-id><pub-id pub-id-type="pmid">21300764</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2820</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuertes</surname><given-names>MB</given-names></name><name><surname>Kacha</surname><given-names>AK</given-names></name><name><surname>Kline</surname><given-names>J</given-names></name><name><surname>Woo</surname><given-names>SR</given-names></name><name><surname>Kranz</surname><given-names>DM</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name></person-group><article-title>Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells</article-title><source>J Exp Med</source><year>2011</year><volume>208</volume><fpage>2005</fpage><lpage>2016</lpage><pub-id pub-id-type="pmcid">PMC3182064</pub-id><pub-id pub-id-type="pmid">21930765</pub-id><pub-id pub-id-type="doi">10.1084/jem.20101159</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reits</surname><given-names>EA</given-names></name><name><surname>Hodge</surname><given-names>JW</given-names></name><name><surname>Herberts</surname><given-names>CA</given-names></name><name><surname>Groothuis</surname><given-names>TA</given-names></name><name><surname>Chakraborty</surname><given-names>M</given-names></name><name><surname>Wansley</surname><given-names>EK</given-names></name><name><surname>Camphausen</surname><given-names>K</given-names></name><name><surname>Luiten</surname><given-names>RM</given-names></name><name><surname>de Ru</surname><given-names>AH</given-names></name><name><surname>Neijssen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy</article-title><source>J Exp Med</source><year>2006</year><volume>203</volume><fpage>1259</fpage><lpage>1271</lpage><pub-id pub-id-type="pmcid">PMC3212727</pub-id><pub-id pub-id-type="pmid">16636135</pub-id><pub-id pub-id-type="doi">10.1084/jem.20052494</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Bode</surname><given-names>B</given-names></name><name><surname>Studer</surname><given-names>G</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Okoniewski</surname><given-names>M</given-names></name><name><surname>Knuth</surname><given-names>A</given-names></name><name><surname>von Boehmer</surname><given-names>L</given-names></name><name><surname>van den Broek</surname><given-names>M</given-names></name></person-group><article-title>Radiotherapy of human sarcoma promotes an intratumoral immune effector signature</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>4843</fpage><lpage>4853</lpage><pub-id pub-id-type="pmid">23861514</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiser</surname><given-names>J</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name></person-group><article-title>Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response</article-title><source>J Immunol Res</source><year>2016</year><volume>2016</volume><elocation-id>8941260</elocation-id><pub-id pub-id-type="pmcid">PMC4893440</pub-id><pub-id pub-id-type="pmid">27314056</pub-id><pub-id pub-id-type="doi">10.1155/2016/8941260</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Leun</surname><given-names>AM</given-names></name><name><surname>Thommen</surname><given-names>DS</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name></person-group><article-title>CD8(+) T cell states in human cancer: insights from single-cell analysis</article-title><source>Nat Rev Cancer</source><year>2020</year><volume>20</volume><fpage>218</fpage><lpage>232</lpage><pub-id pub-id-type="pmcid">PMC7115982</pub-id><pub-id pub-id-type="pmid">32024970</pub-id><pub-id pub-id-type="doi">10.1038/s41568-019-0235-4</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Kurachi</surname><given-names>M</given-names></name></person-group><article-title>Molecular and cellular insights into T cell exhaustion</article-title><source>Nat Rev Immunol</source><year>2015</year><volume>15</volume><fpage>486</fpage><lpage>499</lpage><pub-id pub-id-type="pmcid">PMC4889009</pub-id><pub-id pub-id-type="pmid">26205583</pub-id><pub-id pub-id-type="doi">10.1038/nri3862</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>DL</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group><article-title>Restoring function in exhausted CD8 T cells during chronic viral infection</article-title><source>Nature</source><year>2006</year><volume>439</volume><fpage>682</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">16382236</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumeh</surname><given-names>PC</given-names></name><name><surname>Harview</surname><given-names>CL</given-names></name><name><surname>Yearley</surname><given-names>JH</given-names></name><name><surname>Shintaku</surname><given-names>IP</given-names></name><name><surname>Taylor</surname><given-names>EJ</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Spasic</surname><given-names>M</given-names></name><name><surname>Henry</surname><given-names>G</given-names></name><name><surname>Ciobanu</surname><given-names>V</given-names></name><etal/></person-group><article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="pmcid">PMC4246418</pub-id><pub-id pub-id-type="pmid">25428505</pub-id><pub-id pub-id-type="doi">10.1038/nature13954</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utzschneider</surname><given-names>DT</given-names></name><name><surname>Charmoy</surname><given-names>M</given-names></name><name><surname>Chennupati</surname><given-names>V</given-names></name><name><surname>Pousse</surname><given-names>L</given-names></name><name><surname>Ferreira</surname><given-names>DP</given-names></name><name><surname>Calderon-Copete</surname><given-names>S</given-names></name><name><surname>Danilo</surname><given-names>M</given-names></name><name><surname>Alfei</surname><given-names>F</given-names></name><name><surname>Hofmann</surname><given-names>M</given-names></name><name><surname>Wieland</surname><given-names>D</given-names></name><etal/></person-group><article-title>T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections</article-title><source>Immunity</source><year>2016</year><volume>45</volume><fpage>415</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">27533016</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Im</surname><given-names>SJ</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Gerner</surname><given-names>MY</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kissick</surname><given-names>HT</given-names></name><name><surname>Burger</surname><given-names>MC</given-names></name><name><surname>Shan</surname><given-names>Q</given-names></name><name><surname>Hale</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Nasti</surname><given-names>TH</given-names></name><etal/></person-group><article-title>Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy</article-title><source>Nature</source><year>2016</year><volume>537</volume><fpage>417</fpage><lpage>421</lpage><pub-id pub-id-type="pmcid">PMC5297183</pub-id><pub-id pub-id-type="pmid">27501248</pub-id><pub-id pub-id-type="doi">10.1038/nature19330</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Moseman</surname><given-names>EA</given-names></name><name><surname>Xu</surname><given-names>HC</given-names></name><name><surname>Manglani</surname><given-names>M</given-names></name><name><surname>Kirby</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>SM</given-names></name><name><surname>Handon</surname><given-names>R</given-names></name><name><surname>Kenyon</surname><given-names>E</given-names></name><name><surname>Elkahloun</surname><given-names>A</given-names></name><etal/></person-group><article-title>The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness</article-title><source>Sci Immunol</source><year>2016</year><volume>1</volume><pub-id pub-id-type="pmcid">PMC5179228</pub-id><pub-id pub-id-type="pmid">28018990</pub-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aai8593</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Held</surname><given-names>W</given-names></name><name><surname>Siddiqui</surname><given-names>I</given-names></name><name><surname>Schaeuble</surname><given-names>K</given-names></name><name><surname>Speiser</surname><given-names>DE</given-names></name></person-group><article-title>Intratumoral CD8(+) T cells with stem cell-like properties: Implications for cancer immunotherapy</article-title><source>Sci Transl Med</source><year>2019</year><volume>11</volume><pub-id pub-id-type="pmid">31645454</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jadhav</surname><given-names>RR</given-names></name><name><surname>Im</surname><given-names>SJ</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>JX</given-names></name><name><surname>Leonard</surname><given-names>WJ</given-names></name><name><surname>Greenleaf</surname><given-names>WJ</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Goronzy</surname><given-names>JJ</given-names></name></person-group><article-title>Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade</article-title><source>Proc Natl Acad Sci U S A</source><year>2019</year><volume>116</volume><fpage>14113</fpage><lpage>14118</lpage><pub-id pub-id-type="pmcid">PMC6628832</pub-id><pub-id pub-id-type="pmid">31227606</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1903520116</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>I</given-names></name><name><surname>Schaeuble</surname><given-names>K</given-names></name><name><surname>Chennupati</surname><given-names>V</given-names></name><name><surname>Fuertes Marraco</surname><given-names>SA</given-names></name><name><surname>Calderon-Copete</surname><given-names>S</given-names></name><name><surname>Pais Ferreira</surname><given-names>D</given-names></name><name><surname>Carmona</surname><given-names>SJ</given-names></name><name><surname>Scarpellino</surname><given-names>L</given-names></name><name><surname>Gfeller</surname><given-names>D</given-names></name><name><surname>Pradervand</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy</article-title><source>Immunity</source><year>2019</year><volume>50</volume><fpage>195</fpage><lpage>211</lpage><elocation-id>e110</elocation-id><pub-id pub-id-type="pmid">30635237</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>BC</given-names></name><name><surname>Sen</surname><given-names>DR</given-names></name><name><surname>Al Abosy</surname><given-names>R</given-names></name><name><surname>Bi</surname><given-names>K</given-names></name><name><surname>Virkud</surname><given-names>YV</given-names></name><name><surname>LaFleur</surname><given-names>MW</given-names></name><name><surname>Yates</surname><given-names>KB</given-names></name><name><surname>Lako</surname><given-names>A</given-names></name><name><surname>Felt</surname><given-names>K</given-names></name><name><surname>Naik</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade</article-title><source>Nat Immunol</source><year>2019</year><volume>20</volume><fpage>326</fpage><lpage>336</lpage><pub-id pub-id-type="pmcid">PMC6673650</pub-id><pub-id pub-id-type="pmid">30778252</pub-id><pub-id pub-id-type="doi">10.1038/s41590-019-0312-6</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sade-Feldman</surname><given-names>M</given-names></name><name><surname>Yizhak</surname><given-names>K</given-names></name><name><surname>Bjorgaard</surname><given-names>SL</given-names></name><name><surname>Ray</surname><given-names>JP</given-names></name><name><surname>de Boer</surname><given-names>CG</given-names></name><name><surname>Jenkins</surname><given-names>RW</given-names></name><name><surname>Lieb</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Barzily-Rokni</surname><given-names>M</given-names></name><etal/></person-group><article-title>Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma</article-title><source>Cell</source><year>2018</year><volume>175</volume><fpage>998</fpage><lpage>1013</lpage><elocation-id>e1020</elocation-id><pub-id pub-id-type="pmcid">PMC6641984</pub-id><pub-id pub-id-type="pmid">30388456</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2018.10.038</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>KA</given-names></name><name><surname>Kuchroo</surname><given-names>M</given-names></name><name><surname>Venkat</surname><given-names>A</given-names></name><name><surname>Khatun</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>William</surname><given-names>I</given-names></name><name><surname>Hornick</surname><given-names>NI</given-names></name><name><surname>Fitzgerald</surname><given-names>BL</given-names></name><name><surname>Damo</surname><given-names>M</given-names></name><name><surname>Kasmani</surname><given-names>MY</given-names></name><etal/></person-group><article-title>A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response</article-title><source>Sci Immunol</source><year>2021</year><volume>6</volume><elocation-id>eabg7836</elocation-id><pub-id pub-id-type="pmcid">PMC8593910</pub-id><pub-id pub-id-type="pmid">34597124</pub-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abg7836</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehn</surname><given-names>D</given-names></name><name><surname>Thimme</surname><given-names>R</given-names></name><name><surname>Lugli</surname><given-names>E</given-names></name><name><surname>de Almeida</surname><given-names>GP</given-names></name><name><surname>Oxenius</surname><given-names>A</given-names></name></person-group><article-title>‘Stem-like’ precursors are the fount to sustain persistent CD8(+) T cell responses</article-title><source>Nat Immunol</source><year>2022</year><volume>23</volume><fpage>836</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">35624209</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharabi</surname><given-names>AB</given-names></name><name><surname>Nirschl</surname><given-names>CJ</given-names></name><name><surname>Kochel</surname><given-names>CM</given-names></name><name><surname>Nirschl</surname><given-names>TR</given-names></name><name><surname>Francica</surname><given-names>BJ</given-names></name><name><surname>Velarde</surname><given-names>E</given-names></name><name><surname>Deweese</surname><given-names>TL</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name></person-group><article-title>Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen</article-title><source>Cancer Immunol Res</source><year>2015</year><volume>3</volume><fpage>345</fpage><lpage>355</lpage><pub-id pub-id-type="pmcid">PMC4390444</pub-id><pub-id pub-id-type="pmid">25527358</pub-id><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0196</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marciscano</surname><given-names>AE</given-names></name><name><surname>Ghasemzadeh</surname><given-names>A</given-names></name><name><surname>Nirschl</surname><given-names>TR</given-names></name><name><surname>Theodros</surname><given-names>D</given-names></name><name><surname>Kochel</surname><given-names>CM</given-names></name><name><surname>Francica</surname><given-names>BJ</given-names></name><name><surname>Muroyama</surname><given-names>Y</given-names></name><name><surname>Anders</surname><given-names>RA</given-names></name><name><surname>Sharabi</surname><given-names>AB</given-names></name><name><surname>Velarde</surname><given-names>E</given-names></name><etal/></person-group><article-title>Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy</article-title><source>Clin Cancer Res</source><year>2018</year><volume>24</volume><fpage>5058</fpage><lpage>5071</lpage><pub-id pub-id-type="pmcid">PMC6532976</pub-id><pub-id pub-id-type="pmid">29898992</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-3427</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lugade</surname><given-names>AA</given-names></name><name><surname>Moran</surname><given-names>JP</given-names></name><name><surname>Gerber</surname><given-names>SA</given-names></name><name><surname>Rose</surname><given-names>RC</given-names></name><name><surname>Frelinger</surname><given-names>JG</given-names></name><name><surname>Lord</surname><given-names>EM</given-names></name></person-group><article-title>Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor</article-title><source>J Immunol</source><year>2005</year><volume>174</volume><fpage>7516</fpage><lpage>7523</lpage><pub-id pub-id-type="pmid">15944250</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Auh</surname><given-names>SL</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Burnette</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Beckett</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Chin</surname><given-names>R</given-names></name><name><surname>Tu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type="pmcid">PMC2713472</pub-id><pub-id pub-id-type="pmid">19349616</pub-id><pub-id pub-id-type="doi">10.1182/blood-2009-02-206870</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname><given-names>K</given-names></name></person-group><article-title>FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors</article-title><source>Pharmacol Ther</source><year>2005</year><volume>108</volume><fpage>308</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">15951022</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arina</surname><given-names>A</given-names></name><name><surname>Beckett</surname><given-names>M</given-names></name><name><surname>Fernandez</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Pitroda</surname><given-names>S</given-names></name><name><surname>Chmura</surname><given-names>SJ</given-names></name><name><surname>Luke</surname><given-names>JJ</given-names></name><name><surname>Forde</surname><given-names>M</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Burnette</surname><given-names>B</given-names></name><etal/></person-group><article-title>Tumor-reprogrammed resident T cells resist radiation to control tumors</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>3959</fpage><pub-id pub-id-type="pmcid">PMC6718618</pub-id><pub-id pub-id-type="pmid">31477729</pub-id><pub-id pub-id-type="doi">10.1038/s41467-019-11906-2</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreatta</surname><given-names>M</given-names></name><name><surname>Corria-Osorio</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>S</given-names></name><name><surname>Cubas</surname><given-names>R</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Carmona</surname><given-names>SJ</given-names></name></person-group><article-title>Interpretation of T cell states from single-cell transcriptomics data using reference atlases</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>2965</fpage><pub-id pub-id-type="pmcid">PMC8137700</pub-id><pub-id pub-id-type="pmid">34017005</pub-id><pub-id pub-id-type="doi">10.1038/s41467-021-23324-4</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreatta</surname><given-names>M</given-names></name><name><surname>Carmona</surname><given-names>SJ</given-names></name></person-group><article-title>UCell: Robust and scalable single-cell gene signature scoring</article-title><source>Comput Struct Biotechnol J</source><year>2021</year><volume>19</volume><fpage>3796</fpage><lpage>3798</lpage><pub-id pub-id-type="pmcid">PMC8271111</pub-id><pub-id pub-id-type="pmid">34285779</pub-id><pub-id pub-id-type="doi">10.1016/j.csbj.2021.06.043</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsui</surname><given-names>C</given-names></name><name><surname>Kretschmer</surname><given-names>L</given-names></name><name><surname>Rapelius</surname><given-names>S</given-names></name><name><surname>Gabriel</surname><given-names>SS</given-names></name><name><surname>Chisanga</surname><given-names>D</given-names></name><name><surname>Knopper</surname><given-names>K</given-names></name><name><surname>Utzschneider</surname><given-names>DT</given-names></name><name><surname>Nussing</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Mason</surname><given-names>T</given-names></name><etal/></person-group><article-title>MYB orchestrates T cell exhaustion and response to checkpoint inhibition</article-title><source>Nature</source><year>2022</year><volume>609</volume><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="pmcid">PMC9452299</pub-id><pub-id pub-id-type="pmid">35978192</pub-id><pub-id pub-id-type="doi">10.1038/s41586-022-05105-1</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Cacchiarelli</surname><given-names>D</given-names></name><name><surname>Grimsby</surname><given-names>J</given-names></name><name><surname>Pokharel</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Morse</surname><given-names>M</given-names></name><name><surname>Lennon</surname><given-names>NJ</given-names></name><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Mikkelsen</surname><given-names>TS</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name></person-group><article-title>The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells</article-title><source>Nat Biotechnol</source><year>2014</year><volume>32</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="pmcid">PMC4122333</pub-id><pub-id pub-id-type="pmid">24658644</pub-id><pub-id pub-id-type="doi">10.1038/nbt.2859</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Packer</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>YA</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name></person-group><article-title>Single-cell mRNA quantification and differential analysis with Census</article-title><source>Nat Methods</source><year>2017</year><volume>14</volume><fpage>309</fpage><lpage>315</lpage><pub-id pub-id-type="pmcid">PMC5330805</pub-id><pub-id pub-id-type="pmid">28114287</pub-id><pub-id pub-id-type="doi">10.1038/nmeth.4150</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosco</surname><given-names>N</given-names></name><name><surname>Swee</surname><given-names>LK</given-names></name><name><surname>Benard</surname><given-names>A</given-names></name><name><surname>Ceredig</surname><given-names>R</given-names></name><name><surname>Rolink</surname><given-names>A</given-names></name></person-group><article-title>Auto-reconstitution of the T-cell compartment by radioresistant hematopoietic cells following lethal irradiation and bone marrow transplantation</article-title><source>Exp Hematol</source><year>2010</year><volume>38</volume><fpage>222</fpage><lpage>232</lpage><elocation-id>e222</elocation-id><pub-id pub-id-type="pmid">20045443</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eng</surname><given-names>J</given-names></name><name><surname>Orf</surname><given-names>J</given-names></name><name><surname>Perez</surname><given-names>K</given-names></name><name><surname>Sawant</surname><given-names>D</given-names></name><name><surname>DeVoss</surname><given-names>J</given-names></name></person-group><article-title>Generation of bone marrow chimeras using X-ray irradiation: comparison to cesium irradiation and use in immunotherapy</article-title><source>J Biol Methods</source><year>2020</year><volume>7</volume><fpage>e125</fpage><pub-id pub-id-type="pmcid">PMC7082502</pub-id><pub-id pub-id-type="pmid">32206674</pub-id><pub-id pub-id-type="doi">10.14440/jbm.2020.314</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Waite</surname><given-names>JC</given-names></name><name><surname>Dhanik</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Zhong</surname><given-names>M</given-names></name><name><surname>Adler</surname><given-names>C</given-names></name><name><surname>Malahias</surname><given-names>E</given-names></name><name><surname>Ni</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Gurer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model</article-title><source>Oncoimmunology</source><year>2020</year><volume>9</volume><elocation-id>1758602</elocation-id><pub-id pub-id-type="pmcid">PMC7458611</pub-id><pub-id pub-id-type="pmid">32923116</pub-id><pub-id pub-id-type="doi">10.1080/2162402X.2020.1758602</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mombaerts</surname><given-names>P</given-names></name><name><surname>Clarke</surname><given-names>AR</given-names></name><name><surname>Rudnicki</surname><given-names>MA</given-names></name><name><surname>Iacomini</surname><given-names>J</given-names></name><name><surname>Itohara</surname><given-names>S</given-names></name><name><surname>Lafaille</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ichikawa</surname><given-names>Y</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name><name><surname>Hooper</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages</article-title><source>Nature</source><year>1992</year><volume>360</volume><fpage>225</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">1359428</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>G</given-names></name><name><surname>Blair</surname><given-names>T</given-names></name><name><surname>Bambina</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>AP</given-names></name><name><surname>Alice</surname><given-names>A</given-names></name><name><surname>Baird</surname><given-names>J</given-names></name><name><surname>Friedman</surname><given-names>D</given-names></name><name><surname>Dowdell</surname><given-names>AK</given-names></name><name><surname>Tomura</surname><given-names>M</given-names></name><name><surname>Grassberger</surname><given-names>C</given-names></name><etal/></person-group><article-title>Fluorescence tracking demonstrates T cell recirculation is transiently impaired by radiation therapy to the tumor</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><elocation-id>11909</elocation-id><pub-id pub-id-type="pmcid">PMC11126658</pub-id><pub-id pub-id-type="pmid">38789721</pub-id><pub-id pub-id-type="doi">10.1038/s41598-024-62871-w</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herter-Sprie</surname><given-names>GS</given-names></name><name><surname>Koyama</surname><given-names>S</given-names></name><name><surname>Korideck</surname><given-names>H</given-names></name><name><surname>Hai</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>YY</given-names></name><name><surname>Buczkowski</surname><given-names>KA</given-names></name><name><surname>Grant</surname><given-names>AK</given-names></name><name><surname>Ullas</surname><given-names>S</given-names></name><name><surname>Rhee</surname><given-names>K</given-names></name><etal/></person-group><article-title>Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer</article-title><source>JCI Insight</source><year>2016</year><volume>1</volume><elocation-id>e87415</elocation-id><pub-id pub-id-type="pmcid">PMC5033933</pub-id><pub-id pub-id-type="pmid">27699275</pub-id><pub-id pub-id-type="doi">10.1172/jci.insight.87415</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><article-title>Global Pattern of CD8(+) T-Cell Infiltration and Exhaustion in Colorectal Cancer Predicts Cancer Immunotherapy Response</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><elocation-id>715721</elocation-id><pub-id pub-id-type="pmcid">PMC8477790</pub-id><pub-id pub-id-type="pmid">34594218</pub-id><pub-id pub-id-type="doi">10.3389/fphar.2021.715721</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name></person-group><article-title>CD8(+) T cell exhaustion in anti-tumour immunity: The new insights for cancer immunotherapy</article-title><source>Immunology</source><year>2023</year><volume>168</volume><fpage>30</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">36190809</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balança</surname><given-names>CC</given-names></name><name><surname>Salvioni</surname><given-names>A</given-names></name><name><surname>Scarlata</surname><given-names>CM</given-names></name><name><surname>Michelas</surname><given-names>M</given-names></name><name><surname>Martinez-Gomez</surname><given-names>C</given-names></name><name><surname>Gomez-Roca</surname><given-names>C</given-names></name><name><surname>Sarradin</surname><given-names>V</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Valle</surname><given-names>C</given-names></name><name><surname>Pont</surname><given-names>F</given-names></name><etal/></person-group><article-title>PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells</article-title><source>JCI Insight</source><year>2021</year><volume>6</volume><pub-id pub-id-type="pmcid">PMC7934837</pub-id><pub-id pub-id-type="pmid">33332284</pub-id><pub-id pub-id-type="doi">10.1172/jci.insight.142513</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prokhnevska</surname><given-names>N</given-names></name><name><surname>Cardenas</surname><given-names>MA</given-names></name><name><surname>Valanparambil</surname><given-names>RM</given-names></name><name><surname>Sobierajska</surname><given-names>E</given-names></name><name><surname>Barwick</surname><given-names>BG</given-names></name><name><surname>Jansen</surname><given-names>C</given-names></name><name><surname>Reyes Moon</surname><given-names>A</given-names></name><name><surname>Gregorova</surname><given-names>P</given-names></name><name><surname>delBalzo</surname><given-names>L</given-names></name><name><surname>Greenwald</surname><given-names>R</given-names></name><etal/></person-group><article-title>CD8(+) T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor</article-title><source>Immunity</source><year>2023</year><volume>56</volume><fpage>107</fpage><lpage>124</lpage><elocation-id>e105</elocation-id><pub-id pub-id-type="pmcid">PMC10266440</pub-id><pub-id pub-id-type="pmid">36580918</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2022.12.002</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luke</surname><given-names>JJ</given-names></name><name><surname>Lemons</surname><given-names>JM</given-names></name><name><surname>Karrison</surname><given-names>TG</given-names></name><name><surname>Pitroda</surname><given-names>SP</given-names></name><name><surname>Melotek</surname><given-names>JM</given-names></name><name><surname>Zha</surname><given-names>Y</given-names></name><name><surname>Al-Hallaq</surname><given-names>HA</given-names></name><name><surname>Arina</surname><given-names>A</given-names></name><name><surname>Khodarev</surname><given-names>NN</given-names></name><name><surname>Janisch</surname><given-names>L</given-names></name><etal/></person-group><article-title>Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors</article-title><source>J Clin Oncol</source><year>2018</year><volume>36</volume><fpage>1611</fpage><lpage>1618</lpage><pub-id pub-id-type="pmcid">PMC5978468</pub-id><pub-id pub-id-type="pmid">29437535</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2017.76.2229</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabbour</surname><given-names>SK</given-names></name><name><surname>Berman</surname><given-names>AT</given-names></name><name><surname>Decker</surname><given-names>RH</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Feigenberg</surname><given-names>SJ</given-names></name><name><surname>Gettinger</surname><given-names>SN</given-names></name><name><surname>Aggarwal</surname><given-names>C</given-names></name><name><surname>Langer</surname><given-names>CJ</given-names></name><name><surname>Simone</surname><given-names>CB</given-names><suffix>2nd</suffix></name><name><surname>Bradley</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial</article-title><source>JAMA Oncol</source><year>2020</year><volume>6</volume><fpage>848</fpage><lpage>855</lpage><pub-id pub-id-type="pmcid">PMC7042914</pub-id><pub-id pub-id-type="pmid">32077891</pub-id><pub-id pub-id-type="doi">10.1001/jamaoncol.2019.6731</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>SF</given-names></name><name><surname>Gold</surname><given-names>KA</given-names></name><name><surname>Gitau</surname><given-names>MM</given-names></name><name><surname>Sumey</surname><given-names>CJ</given-names></name><name><surname>Lohr</surname><given-names>MM</given-names></name><name><surname>McGraw</surname><given-names>SC</given-names></name><name><surname>Nowak</surname><given-names>RK</given-names></name><name><surname>Jensen</surname><given-names>AW</given-names></name><name><surname>Blanchard</surname><given-names>MJ</given-names></name><name><surname>Fischer</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase iB Study</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><fpage>2427</fpage><lpage>2437</lpage><pub-id pub-id-type="pmcid">PMC7365766</pub-id><pub-id pub-id-type="pmid">32479189</pub-id><pub-id pub-id-type="doi">10.1200/JCO.19.03156</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Dafni</surname><given-names>U</given-names></name><name><surname>Belka</surname><given-names>C</given-names></name><name><surname>Guckenberger</surname><given-names>M</given-names></name><name><surname>Irigoyen</surname><given-names>A</given-names></name><name><surname>Nadal</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>A</given-names></name><name><surname>Vees</surname><given-names>H</given-names></name><name><surname>Pless</surname><given-names>M</given-names></name><etal/></person-group><article-title>Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial</article-title><source>Lung Cancer</source><year>2019</year><volume>133</volume><fpage>83</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">31200833</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>JW</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Menon</surname><given-names>H</given-names></name><name><surname>Klein</surname><given-names>K</given-names></name><name><surname>Cushman</surname><given-names>TR</given-names></name><name><surname>Verma</surname><given-names>V</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Shroff</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC</article-title><source>J Thorac Oncol</source><year>2020</year><volume>15</volume><fpage>1919</fpage><lpage>1927</lpage><pub-id pub-id-type="pmcid">PMC10600713</pub-id><pub-id pub-id-type="pmid">32916308</pub-id><pub-id pub-id-type="doi">10.1016/j.jtho.2020.08.022</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altorki</surname><given-names>NK</given-names></name><name><surname>McGraw</surname><given-names>TE</given-names></name><name><surname>Borczuk</surname><given-names>AC</given-names></name><name><surname>Saxena</surname><given-names>A</given-names></name><name><surname>Port</surname><given-names>JL</given-names></name><name><surname>Stiles</surname><given-names>BM</given-names></name><name><surname>Lee</surname><given-names>BE</given-names></name><name><surname>Sanfilippo</surname><given-names>NJ</given-names></name><name><surname>Scheff</surname><given-names>RJ</given-names></name><name><surname>Pua</surname><given-names>BB</given-names></name><etal/></person-group><article-title>Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><fpage>824</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">34015311</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Connolly</surname><given-names>E</given-names></name><name><surname>Aiello</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Chappa</surname><given-names>P</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Tippitak</surname><given-names>P</given-names></name><name><surname>Clark</surname><given-names>T</given-names></name><name><surname>Cardenas</surname><given-names>M</given-names></name><name><surname>Prokhnevska</surname><given-names>N</given-names></name><etal/></person-group><article-title>Radiation and anti-PD-L1 synergize by stimulating a stem-like T cell population in the tumor-draining lymph node</article-title><source>Res Sq</source><year>2024</year><pub-id pub-id-type="doi">10.21203/rs.3.rs-3921977/v1</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sia</surname><given-names>J</given-names></name><name><surname>Hagekyriakou</surname><given-names>J</given-names></name><name><surname>Chindris</surname><given-names>I</given-names></name><name><surname>Albarakati</surname><given-names>H</given-names></name><name><surname>Leong</surname><given-names>T</given-names></name><name><surname>Schlenker</surname><given-names>R</given-names></name><name><surname>Keam</surname><given-names>SP</given-names></name><name><surname>Williams</surname><given-names>SG</given-names></name><name><surname>Neeson</surname><given-names>PJ</given-names></name><name><surname>Johnstone</surname><given-names>RW</given-names></name><name><surname>Haynes</surname><given-names>NM</given-names></name></person-group><article-title>Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2021</year><volume>111</volume><fpage>502</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">34023423</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name></person-group><article-title>Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non-Small-Cell Lung Cancer</article-title><source>Front Mol Biosci</source><year>2022</year><volume>9</volume><elocation-id>786864</elocation-id><pub-id pub-id-type="pmcid">PMC8819084</pub-id><pub-id pub-id-type="pmid">35141280</pub-id><pub-id pub-id-type="doi">10.3389/fmolb.2022.786864</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran Chau</surname><given-names>V</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Gerbe de Thore</surname><given-names>M</given-names></name><name><surname>Meziani</surname><given-names>L</given-names></name><name><surname>Mondini</surname><given-names>M</given-names></name><name><surname>O’Connor</surname><given-names>MJ</given-names></name><name><surname>Deutsch</surname><given-names>E</given-names></name><name><surname>Clemenson</surname><given-names>C</given-names></name></person-group><article-title>Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models</article-title><source>Br J Cancer</source><year>2020</year><volume>123</volume><fpage>762</fpage><lpage>771</lpage><pub-id pub-id-type="pmcid">PMC7463250</pub-id><pub-id pub-id-type="pmid">32546832</pub-id><pub-id pub-id-type="doi">10.1038/s41416-020-0931-6</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LM</given-names></name><name><surname>Yadav</surname><given-names>R</given-names></name><name><surname>Serban</surname><given-names>M</given-names></name><name><surname>Arias</surname><given-names>O</given-names></name><name><surname>Seuntjens</surname><given-names>J</given-names></name><name><surname>Ybarra</surname><given-names>N</given-names></name></person-group><article-title>Validation of an orthotopic non-small cell lung cancer mouse model, with left or right tumor growths, to use in conformal radiotherapy studies</article-title><source>PLoS One</source><year>2023</year><volume>18</volume><elocation-id>e0284282</elocation-id><pub-id pub-id-type="pmcid">PMC10101527</pub-id><pub-id pub-id-type="pmid">37053154</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0284282</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabien</surname><given-names>N</given-names></name><name><surname>Bergerot</surname><given-names>I</given-names></name><name><surname>Maguer-Satta</surname><given-names>V</given-names></name><name><surname>Orgiazzi</surname><given-names>J</given-names></name><name><surname>Thivolet</surname><given-names>C</given-names></name></person-group><article-title>Pancreatic lymph nodes are early targets of T cells during adoptive transfer of diabetes in NOD mice</article-title><source>J Autoimmun</source><year>1995</year><volume>8</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">7575994</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>SR</given-names></name><name><surname>Morgan</surname><given-names>MJ</given-names></name><name><surname>Ball</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>J</given-names></name><name><surname>Faik</surname><given-names>P</given-names></name></person-group><article-title>Sequence characterization of alleles Gpi1-Sa and Gpi1-Sb at the glucose phosphate isomerase structural locus</article-title><source>Mamm Genome</source><year>1995</year><volume>6</volume><fpage>537</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">8589524</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trowbridge</surname><given-names>IS</given-names></name><name><surname>Mazauskas</surname><given-names>C</given-names></name></person-group><article-title>Immunological properties of murine thymus-dependent lymphocyte surface glycoproteins</article-title><source>Eur J Immunol</source><year>1976</year><volume>6</volume><fpage>557</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">61878</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogquist</surname><given-names>KA</given-names></name><name><surname>Jameson</surname><given-names>SC</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name><name><surname>Howard</surname><given-names>JL</given-names></name><name><surname>Bevan</surname><given-names>MJ</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name></person-group><article-title>T cell receptor antagonist peptides induce positive selection</article-title><source>Cell</source><year>1994</year><volume>76</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">8287475</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilfillan</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>CJ</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Haynes</surname><given-names>NM</given-names></name><name><surname>Rapaport</surname><given-names>AS</given-names></name><name><surname>Boles</surname><given-names>KS</given-names></name><name><surname>Andrews</surname><given-names>DM</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><article-title>DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors</article-title><source>J Exp Med</source><year>2008</year><volume>205</volume><fpage>2965</fpage><lpage>2973</lpage><pub-id pub-id-type="pmcid">PMC2605240</pub-id><pub-id pub-id-type="pmid">19029380</pub-id><pub-id pub-id-type="doi">10.1084/jem.20081752</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scarborough</surname><given-names>J</given-names></name><name><surname>Mueller</surname><given-names>F</given-names></name><name><surname>Arban</surname><given-names>R</given-names></name><name><surname>Dorner-Ciossek</surname><given-names>C</given-names></name><name><surname>Weber-Stadlbauer</surname><given-names>U</given-names></name><name><surname>Rosenbrock</surname><given-names>H</given-names></name><name><surname>Meyer</surname><given-names>U</given-names></name><name><surname>Richetto</surname><given-names>J</given-names></name></person-group><article-title>Preclinical validation of the micropipette-guided drug administration (MDA) method in the maternal immune activation model of neurodevelopmental disorders</article-title><source>Brain Behav Immun</source><year>2020</year><volume>88</volume><fpage>461</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">32278850</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becht</surname><given-names>E</given-names></name><name><surname>McInnes</surname><given-names>L</given-names></name><name><surname>Healy</surname><given-names>J</given-names></name><name><surname>Dutertre</surname><given-names>CA</given-names></name><name><surname>Kwok</surname><given-names>IWH</given-names></name><name><surname>Ng</surname><given-names>LG</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name></person-group><article-title>Dimensionality reduction for visualizing single-cell data using UMAP</article-title><source>Nat Biotechnol</source><year>2018</year><pub-id pub-id-type="pmid">30531897</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>JH</given-names></name><name><surname>Simonds</surname><given-names>EF</given-names></name><name><surname>Bendall</surname><given-names>SC</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><name><surname>Amir el</surname><given-names>AD</given-names></name><name><surname>Tadmor</surname><given-names>MD</given-names></name><name><surname>Litvin</surname><given-names>O</given-names></name><name><surname>Fienberg</surname><given-names>HG</given-names></name><name><surname>Jager</surname><given-names>A</given-names></name><name><surname>Zunder</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>184</fpage><lpage>197</lpage><pub-id pub-id-type="pmcid">PMC4508757</pub-id><pub-id pub-id-type="pmid">26095251</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.047</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germain</surname><given-names>PL</given-names></name><name><surname>Lun</surname><given-names>A</given-names></name><name><surname>Garcia Meixide</surname><given-names>C</given-names></name><name><surname>Macnair</surname><given-names>W</given-names></name><name><surname>Robinson</surname><given-names>MD</given-names></name></person-group><article-title>Doublet identification in single-cell sequencing data using scDblFinder</article-title><source>F1000Res</source><year>2021</year><volume>10</volume><fpage>979</fpage><pub-id pub-id-type="pmcid">PMC9204188</pub-id><pub-id pub-id-type="pmid">35814628</pub-id><pub-id pub-id-type="doi">10.12688/f1000research.73600.2</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Kowalski</surname><given-names>MH</given-names></name><name><surname>Choudhary</surname><given-names>S</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Hartman</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Molla</surname><given-names>G</given-names></name><name><surname>Madad</surname><given-names>S</given-names></name><name><surname>Fernandez-Granda</surname><given-names>C</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><article-title>Dictionary learning for integrative, multimodal and scalable single-cell analysis</article-title><source>Nat Biotechnol</source><year>2024</year><volume>42</volume><fpage>293</fpage><lpage>304</lpage><pub-id pub-id-type="pmcid">PMC10928517</pub-id><pub-id pub-id-type="pmid">37231261</pub-id><pub-id pub-id-type="doi">10.1038/s41587-023-01767-y</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreatta</surname><given-names>M</given-names></name><name><surname>Berenstein</surname><given-names>AJ</given-names></name><name><surname>Carmona</surname><given-names>SJ</given-names></name></person-group><article-title>scGate: marker-based purification of cell types from heterogeneous single-cell RNA-seq datasets</article-title><source>Bioinformatics</source><year>2022</year><volume>38</volume><fpage>2642</fpage><lpage>2644</lpage><pub-id pub-id-type="pmcid">PMC9048671</pub-id><pub-id pub-id-type="pmid">35258562</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btac141</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Pre-existing intratumoral CD8<sup>+</sup> T-cells are sufficient for the therapeutic efficacy of radiotherapy.</title><p>(A) Experimental setup: C57BL/6 mice (RT<sup>+</sup>FTY720 n=10, the rest n=9 per condition) were injected subcutaneously with 8x10<sup>5</sup> MC38-OVA cells in matrigel:PBS (1:2). Fifteen days later, some groups received radiotherapy (RT; 20 Gy) or not (UNTR). Starting 1 day before radiotherapy, some groups received 20 μg FTY720 per os every second day until the endpoint. Tumors were analyzed nine days after radiotherapy. (B) Tumor size (length x breadth) was measured by caliper. (C) Tumor weight (D) Number of CD8<sup>+</sup> T-cells per gram of tumor. (E) Percentage of CD62L, PD-1, PD-1 and TIM-3 expressing CD8<sup>+</sup> T-cells. (F) Percentage of GZMB and Ki-67 expressing CD8<sup>+</sup> T-cells and SIINFEKL-specific CD8<sup>+</sup> T-cells, determined by H-2Kb OVA tetramer. (G) Percentage of GZMB and Ki-67 expressing SIINFEKL-specific CD8<sup>+</sup> T-cells. The bar indicates the mean ±SD. Groups were statistically compared using one-way ANOVA with Tukey’s multiple comparison correction. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p></caption><graphic xlink:href="EMS199535-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>The initial loss of pre-existing intratumoral CD8<sup>+</sup> T-cells is followed by proliferation after radiotherapy.</title><p>(A) Experimental setup: C57BL/6 mice (n=9 per condition) were injected subcutaneously with 8x10<sup>5</sup> MC38-OVA cells in matrigel:PBS (1:2). Fifteen (d3) or seventeen (d1) days later, some groups received radiotherapy (RT; 20 Gy) or not (UNTR). Starting 1 day before radiotherapy, all groups received 20 μg FTY720 per os every second day until the endpoint. Tumors were analyzed one or three days after radiotherapy. (B) Tumor weight. (C) Number of CD8<sup>+</sup> T-cells per gram of tumor. (D) Experimental setup: C57BL/6 mice (UNTR n=11, the rest n=10 per condition) were injected subcutaneously with 8x10<sup>5</sup> MC38-OVA cells in matrigel:PBS (1:2). Fifteen (d9) or eighteen (d6) days later, some groups received radiotherapy (RT; 20 Gy) or not (UNTR). Starting 1 day before radiotherapy, all groups received 20 μg FTY720 per os every second day until the endpoint. Tumors were analyzed six or nine days after radiotherapy. (E) Tumor size (length x breadth) was measured by caliper. (F) Tumor weight (G) Number of CD8<sup>+</sup> T-cells per gram of tumor. (H) Percentage of CD62L, PD-1, PD-1 and TIM-3 expressing CD8<sup>+</sup> T-cells. (I) Percentage of GZMB and Ki-67 expressing CD8<sup>+</sup> T-cells and SIINFEKL-specific CD8<sup>+</sup> T-cells, determined by H-2Kb OVA tetramer. The bar indicates the mean ±SD. Groups were statistically compared using one-way ANOVA with Tukey’s multiple comparison correction. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic xlink:href="EMS199535-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Radiotherapy promotes the proliferation of pre-existing intratumoral stem-like CD8<sup>+</sup> T-cells.</title><p>(A) Experimental setup: C57BL/6 mice (UNTR<sup>+</sup>FTY720 n=7, the rest n=8 per condition) were injected subcutaneously with 8x105 MC38-OVA cells in matrigel:PBS (1:2). Fifteen days later, some groups received radiotherapy (RT; 20 Gy) or not (UNTR). Starting 1 day before radiotherapy, all groups received 20 μg FTY720 per os every second day until the endpoint. Six days after radiotherapy, tumor samples were hashed and CD8<sup>+</sup> T-cells were sorted using flow cytometry. Samples were prepared using the BD Rhapsody platform and sequenced on the Illumina NovaSeq X. (B) UMAP representation of annotated CD8<sup>+</sup> T-cell subsets, determined by ProjectTILs package. (C) Pie chart showing frequencies of CD8<sup>+</sup> T-cell subsets per condition. (D) UMAP representation of stem-like CD8<sup>+</sup> T-cell clusters. (E) Heatmap illustrates signature scores (determined by UCell package) across different stem-like CD8<sup>+</sup> T-cell clusters. (F) Percentage of UMAP clusters 1 and 3. (G) Percentage of proliferating stem-like CD8<sup>+</sup> T-cells (defined by a G1S or G2M score &gt;0.1), determined by UCell package. (H) <italic>Mki67</italic> expression shown as log-normalized counts. The bar indicates the mean ±SD. Groups were statistically compared using one-way ANOVA with Tukey’s multiple comparison correction. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p></caption><graphic xlink:href="EMS199535-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Depletion of TCF-1<sup>+</sup> cells impairs the efficacy of radiotherapy.</title><p>(A) Experimental setup: Tcf7DTR-GFP→C57BL/6 mice (UNTR, RT n=8, UNTR+DTX n=7, RT<sup>+</sup>DTX n=9) bone marrow transplant was performed as described (22685313). After 8 weeks, the mice were injected subcutaneously with 8x105 MC38-OVA-GFP cells in matrigel:PBS (1:2). One day before tumor injection and one day before radiotherapy, the remaining host T-cells were depleted by a double intraperitoneal injection of 500 μg of anti-Thy1.2 (30H12). Fifteen days after tumor injection, some groups received radiotherapy (RT; 20 Gy) or not (UNTR). Starting 1 day before radiotherapy, all groups received 20 μg FTY720 per os every second day, some groups received 250 ng diphtheria toxin (DTX) intraperitoneal injection twice per week, whereas the other groups received PBS until the endpoint. Tumors were analyzed nine days after radiotherapy. (B) Tumor size (length x breadth) was measured by caliper. (C) Tumor weight (D) Number of CD8<sup>+</sup> T-cells per gram of tumor. (E) Number of PD-1 and PD-1 and TIM-3 expressing CD8<sup>+</sup> T-cells per gram of tumor. (F) Number of GZMB and Ki-67 expressing CD8<sup>+</sup> T-cells, SIINFEKL-specific (determined by H-2Kb OVA tetramer) and p15-specific (determined by H-2Kb p15E tetramer) CD8<sup>+</sup> T-cells per gram of tumor. Each symbol represents one mouse. The bar indicates the mean ±SD. Groups were statistically compared using one-way ANOVA with Tukey’s multiple comparison correction. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic xlink:href="EMS199535-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Stem-like CD8<sup>+</sup> T-cells differentiate and proliferate after radiotherapy.</title><p>(A) Experimental setup: C57BL/6 mice (n=15) were injected subcutaneously with 3x10<sup>5</sup> LLC-OVA cells in matrigel:PBS (1:2). Three days later, all mice received an intravenous injection of magnetically enriched OT-I x Tcf7<sup>DTR-GFP</sup> (CD45.1) CD8<sup>+</sup> T-cells (10<sup>5</sup> cells per mouse). Seven days later, tumors were processed, and stem-like (TCF-1<sup>+</sup>PD-1<sup>+</sup>) and effector (TCF-1—PD<sup>-</sup>1<sup>+</sup>) CD8<sup>+</sup> T-cells were sorted by flow cytometry. These cells were then intravenously injected into LLC-OVA-bearing Tcrb<sup>-/-</sup> mice (3000 cells per mouse). One day later, all mice (n=6 per condition) received radiotherapy (RT; 20 Gy). Tumors and tumor-draining lymph nodes were analyzed nine days after radiotherapy. (B) Tumor size (length x breadth) was measured by caliper. (C) Tumor weight. (D) Presence of adoptively transferred cells was evaluated by measuring the percentage of CD45.1<sup>+</sup> cells among CD45<sup>+</sup> cells in the blood six days after radiotherapy. (E-F) Number of CD8<sup>+</sup> T-cells per lymph node (E) and per gram of tumor (F). Each symbol represents one mouse. The bar indicates the mean ±SD. Groups were statistically compared using the Mann-Whitney U test. *p&lt;0.05, **p&lt;0.01.</p></caption><graphic xlink:href="EMS199535-f005"/></fig></floats-group></article>